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i 
Abstract 
The prediction of percutaneous absorption is of enormous importance for the effective 
design, development and quality assessment of topical and transdermal formulations. In vitro 
diffusion experiments are widely carried out for such predictions and are of substantial interest 
across the pharmaceutical and cosmetic industries. Human or animal skin, usually excised, are 
often used in in vitro drug diffusion studies. However, difficulties in obtaining the mammalian 
skin and variation in their permeability directed researchers towards using synthetic membranes 
as skin mimics in preformulation screening experiments, where a large number of experiments 
are required. Polydimethylsiloxane (PDMS) membranes have been accepted as the most 
commonly used in vitro skin mimic because of their homogeneity, uniformity and skin-
analogous rate-limiting permeation properties. 
This thesis investigates the effects of ionisation and surfactants on the permeation of 
pharmaceutical compounds of varied physicochemical properties through PDMS membranes 
using a flow-through diffusion cell system. Data suggests that drug permeation had a 
dependency on the extent of its ionisation, with the permeation being more favourable for the 
more unionised form of a drug. All of the surfactants studied were found to reduce the 
permeation of the drugs, with an inverse relationship being observed between the surfactant 
concentration and the amount of drug permeated. DSC (differential scanning calorimetry), SEM 
(scanning electron microscopy), FTIR (Fourier transform infrared) and NMR (nuclear magnetic 
resonance) spectroscopy were employed to study the interactions between the membrane and 
the surfactants. Results indicated that the permeation effects of the surfactants are a 
consequence of the interactions between the drugs and surfactant micelles, and/or the 
membrane and the surfactants. 
Air plasma treatment was used to modify the PDMS surfaces to become hydrophilic, 
which was confirmed by water contact angle (WCA) and SEM-EDX analysis. The permeation 
data for the modified membranes revealed that the plasma-induced hydrophilicity significantly 
reduced the fluxes of the hydrophobic compounds, while not affecting that of the hydrophilic 
drug. Aging studies of the plasma-treated membranes showed that the hydrophilic surfaces were 
maintained even after 8 weeks under airtight storage conditions.  
In summary, ionisation and surfactant effects on drug permeation across PDMS were 
thoroughly investigated, and plasma treatment was found to be a stable, economic and 
convenient method of modifying PDMS to offer skin-like slower drug permeation i.e. to 
produce a potential in vitro skin mimic.  
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1 
Chapter 1: Introduction 
 
1.1 Background 
 Topical and transdermal administration of drugs has received enormous interest as it 
fulfils a variety of medical and cosmetic purposes including the treatment of local skin 
disorders, therapy of local muscle injury, UV protection and systemic drug delivery. Such 
interest has prompted a significant research effort into the analysis of drug permeation 
through skin, and the prediction of such permeation (Anissimov & Roberts 2011). A number 
of in vitro methods have been established for the prediction of percutaneous permeation. 
Examples include mathematical models, cultured skin alternatives and synthetic membranes 
(Waters 2015). These predictive techniques are important not only for the design and 
development of novel formulations, but also for the quality assessment of products (Shah et 
al.  1999), and toxicity screening (Zorin et al.  1999). Amongst the predictive models, 
synthetic membranes have found extensive application as accepted in vitro skin mimics, 
based on their competitive advantages including better reproducibility, reduced cost (Ng et 
al.  2012), and simplicity of use. One such widely used skin mimic for studying transdermal 
permeation is poly(dimethylsiloxane) (PDMS) membrane (Waters et al. 2013), simply 
known as silicone membrane. The fact that PDMS membrane is a simplified model of skin, 
means that it has the advantage of producing greater reproducibility in data acquired yet has 
the disadvantage of behaving differently to skin under certain conditions. Several factors 
have already been reported to effect permeation through PDMS including membrane 
thickness (Lee et al. 2008), solvent selection (Dias et al. 2007; Shahzad et al. 2014) and 
temperature (Waters et al. 2013). Furthermore, surfactants are a group of compounds that are 
known to have the ability to alter skin permeation (Walters et al. 1993; Shokri et al. 2001), 
and have been studied, though to a very limited extent, to find their effect on the permeation 
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of compounds through PDMS membrane (Waters et al. 2013). The role of compound 
ionisation (as a result of formulation pH) on permeation across PDMS has also received very 
little attention, and is not well understood. Another influential factor on permeation is 
changing the PDMS surface, for example, by making the surface more hydrophilic, by means 
of chemical or physical treatment. Numerous applications have been reported for modified 
PDMS membrane (Hsu & Chang 2015; Ko et al. 2008), yet the impact of such modification 
on in vitro drug diffusion has received very little attention, and hence requires a thorough 
investigation. Understanding all of the above-mentioned aspects could further the suitability 
of PDMS membrane as an in vitro skin mimic, especially in the design and development of 
topical and transdermal formulations.            
       
1.2 Human skin: structure and function  
 The skin is considered the most complex and largest organ in the human body 
(Ghafourian et al. 2010), and provides a multifunctional interface between the body and the 
external environment. The main purpose of the skin is to protect the body from the 
penetration of harmful chemicals (Gupta et al.  2016) i.e. an excellent biological barrier. The 
skin contributes to the body weight by about 4 %, and is 102 – 104 times less permeable than 
a blood capillary wall (Cevc & Vierl 2010). It has a surface area of approximately 1.5 – 2 m2, 
with a wide-ranging thickness according to gender and anatomical site (Pegoraro et al.  2012). 
Below are a few examples of the functions of the skin: 
 Protects the internal body against foreign pathogens, chemicals, allergens, UV 
radiation. 
 Prevents the loss of water, electrolytes and macromolecules. 
 Helps in the synthesis of Vitamin D 
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 Forms an extensive sensory surface for sensing touch, pressure, heat, cold and 
pain (Moss et al. 2015). 
 Plays a role in homeostasis by regulating body temperature and blood pressure 
(Benson & Watkinson 2012). 
The skin is a multi-layered organ composed of three distinctive histological layers – 
the outer epidermis, the dermis and the hypodermis (also known as the subcutaneous tissue) 
(Fig. 1.1 A). 
 
 
 
 
 
 
 
Fig. 1.1: (A) Cross-section of human skin (B) Human epidermis (Pegoraro et al. 2012)  
 The epidermis is the outermost, and also the thinnest, part of the skin. It is a multi-
layered epithelium, consisting of four, or often five, separate layers – the stratum corneum 
(SC), the stratum lucidum (present in thick skin), the stratum granulosum, the stratum 
spinosum and the stratum germinativum (also known as the basal layer) (Fig.1.1. B). The 
outermost layer of the epidermis, and hence of the skin, is the stratum corneum, which is 10-
20 µm thick. It is highly compacted, and acts as the primary barrier for the permeation of 
drugs. The SC consists of several layers of corneocytes with about 10 lipid bilayers 
compacted between two adjacent corneocyte layers. These lipid bilayers form the 
intercellular lipid matrix of the SC (Mitragotri 2003). The next layer of the skin is dermis (or 
corium), which lies immediately above the hypodermis. It contains blood vessels, lymphatic 
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vessels, nerve tissues, sense receptors, hair follicles, sweat glands and sebaceous glands (Fig. 
1.1. A: numbered as 1, 2, 3, 4, 5, 6 respectively). It is usually 1 – 5 mm in thickness (Moss 
et al. 2015), and consists of collagen, elastin, glycosaminoglycan, salts and water. 
Underneath the dermis is the hypodermis, the deepest region of the skin. The hypodermis is 
rich in collagen and fat. Its main functions are insulation and shock-absorption (Dias et al. 
2001; Pegoraro et al.  2012).    
 The skin, in recent years, has widely been accepted as a site for topical and systemic 
drug delivery. Topical application of drugs is useful when the target site is the skin. This type 
of drug delivery is usually intended to treat local skin disorders, or for cosmetic purposes. 
Examples of topical formulations include ointment, gel, cream, powder, foam, lotion and 
spray (Mugglestone et al. 2012). For systemic administration, drugs are delivered through 
the transdermal route using a vehicle such as a transdermal patch (Lenz & Gillespie 2011).     
  
1.3 Transdermal drug delivery 
 In transdermal drug delivery or TDD, therapeutic compounds are administered 
continuously through the skin. The last few decades have resulted in significant development 
and success in the area of transdermal drug delivery (Hillery et al. 2001). The success of the 
TDD method can be evidenced by the fact that, currently in the USA, more than 35 
transdermal products are approved for use to treat a number of conditions including severe 
pain, hypertension, nicotine dependence, female menopause and contraception (Thomas & 
Finnin 2004). There are also several products in the late-stage development phase that can 
potentially extend the use of TDD into complex therapeutic areas such as Parkinson’s disease, 
female sexual dysfunction and attention deficit and hyperactivity disorder (ADHD). Another 
interesting application of the TDD method is the possibility of administering vaccines 
through the skin, to directly target the immune cells of the viable epidermis and initiate a 
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strong immune reaction (Pegoraro et al. 2012).  Drug delivery via the transdermal route is 
considered a useful alternative to the intravenous or oral route, and the benefits have been 
well-documented. Below are several examples: 
 TDD offers improved patient compliance (Thomas & Finnin 2004). 
 No hospitalisation is required. 
 The treatment mode is non-invasive. 
 The affected area can be targeted selectively. 
 First-pass effect can be avoided. 
 Drug pharmacokinetics can be enhanced. 
 The release of drugs can be controlled and sustained (Pegoraro et al. 2012).  
 
1.4 Transdermal routes of drug permeation  
 Drugs can permeate through the skin by four possible routes (Mitragotri 2003): 
i. Free-volume diffusion across lipid bilayers 
ii. Lateral diffusion along lipid bilayers 
iii. Diffusion through pores 
iv. Diffusion through the transappendageal route  
The transappendageal route is also known as the ‘shunt route’, for the fact that the 
skin has several natural openings, for example, sweat glands, hair follicles and wrinkles, 
which enable drug permeation through the skin. However, this route only constitutes 0.1 % 
of the total surface of the skin, and hence, is limited (Pegoraro et al. 2012). Transdermal 
transport of drugs, especially hydrophobic ones, is predominantly governed by the skin’s 
lipid bilayers (Mitragotri 2003), which create a lipophilic route of permeation. When 
permeating through the lipid bilayers of the intercellular lipid matrix, drugs can also diffuse 
through the corneocytes, though this hydrophilic route is unfavourable for most drugs. Hence, 
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the preferred pathway for transdermal permeation is the intercellular route – a continuous but 
twisted pathway across the intercellular lipid matrix (Fig. 1.2) (Pegoraro et al. 2012).  
           
 
 
 
 
 
Fig. 1.2: Transepidermal routes of drug diffusion: transcellular and intercellular (Pegoraro 
et al. 2012). 
 
1.5 Factors affecting drug permeation  
 Skin permeation of drug involves several processes including release of the drug from 
the formulation, followed by partitioning into, and diffusion through the stratum corneum, 
then uptake into other skin layers and penetration through to the deeper tissues or cutaneous 
circulation (Benson & Watkinson 2012). The rate and extent to which a drug permeates the 
skin depend not only on physiological factors but also on the physicochemical properties of 
the drug, and the formulation (Moss et al. 2015).  
 
1.5.1 Physicochemical properties of penetrant     
The permeation of drugs, into and across, the skin is known to be significantly 
affected by their physicochemical properties such as partition coefficient, molecular size and 
shape, aqueous solubility and ionisation. Le and Lippold found a linear relationship between 
permeability and partition coefficient for the permeation of homologous esters of nicotinic 
acid through the skin (Le & Lippold 1995). Moss et al. discussed that compounds with an 
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intermediate lipophilicity – having a log log P of between 1 and 3 – would permeate the skin 
via both lipophilic and hydrophilic routes but the intercellular pathway would predominate, 
and lipophilic compounds (those having a log P greater than 3) would traverse predominantly 
through the intercellular pathway (Moss et al. 2015). Molecular size and shape of a drug is 
also known to affect skin permeation. It has been shown that permeant size is inversely 
related to skin permeation (Idson 1975; Pugh et al. 2000). Scheuplein and Blank observed a 
decrease in the skin permeability of steroids when polar groups were incorporated in their 
structures (Scheuplein et al.  1969). Another important factor affecting transdermal 
permeation is the drug solubility in the lipid domain of the stratum corneum. The melting 
point (MP) of a drug is often used, in predictive models, to determine such solubility 
(Ostrenga et al. 1971). Drugs with a relatively low melting point, for example, nicotine (MP 
-79 °C) and nitroglycerine (13.5 °C), are very good skin penetrants (Benson & Watkinson 
2012). Skin permeation can also be affected by the concentration of a drug in a topical 
formulation. Moss et al. mentioned that an increase in drug concentration would increase the 
amount of drug permeated through the skin (Moss et al. 2015). Permeation also depends on 
the ionisation state of a drug, in terms of its pKa and the formulation pH. As the stratum 
corneum is predominantly lipophilic in nature, the unionised species are more likely to 
penetrate the skin than the ionised species. Therefore, the adjustment of formulation pH will 
alter the rate and extent of drug permeation across the skin (Moss et al. 2006).    
 
1.5.2 Physiological factors     
Besides the physicochemical properties of a penetrant, there are a number of 
physiological factors that can alter skin permeation. One of the important factors is skin 
condition. Generally, skin permeability relates to the permeation of penetrants across healthy 
and intact skin. Hence, the ‘quality’ of the skin is significant in experiments that are intended 
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to determine skin absorption. Diseases, such as eczema, or mechanical damage, such as cuts 
and abrasions, or chemical burns may disrupt the skin barrier and hence skin permeability 
(Moss et al. 2015). For example, one study found a 46-fold and 146-fold increase in the skin 
permeation of salicylic acid in mild dermatitis and severe dermatitis, respectively, relative to 
healthy skin (Benfeldt et al. 1999). There are some other physiological factors that can have 
a profound effect on skin permeation. These include skin hydration, skin age, anatomical site 
and skin temperature. Generally, permeation rate increases with an increase in skin 
temperature. It is known that skin permeation is initially a process of diffusion and therefore 
temperature dependant. Another factor that affects drug permeation is skin hydration, which 
is known to enhance the permeation of most chemicals – by elevating the rate of diffusion 
(Moss et al. 2015). With regards to skin age, the skin structure – in particular, the lipid 
composition – changes significantly as the skin ages which can alter the skin permeability of 
drugs (Benson & Watkinson 2012). For example, the skin permeation of topical steroids has 
been found to be greater in children than in adults (Idson 1975). However, not all penetrants 
show the age-related permeability pattern. One example is the permeation of sufentanil and 
fentanyl, where neither gender nor age were found to affect their permeation through skin 
(Roy & Flynn 1990). One widely studied area – with regards to percutaneous absorption –  
is skin permeability at different body sites (Benson & Watkinson 2012).  Wide variations in 
skin permeation rates are generally observed across different anatomical sites in the same 
individual and between different individuals. Attempts have been made to rank body sites in 
terms of skin permeability. Below is an example of such rankings: 
posterior aricular skin > scrotum > head and neck > abdomen > forearm > thigh > 
instep > heel > planter (Moss et al. 2015) 
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1.5.3 Formulation effects    
As mentioned previously, skin permeation involves a series of steps – diffusion and 
partitioning from, and between, a number of compartments within the several skin layers. 
Formulations can be tailored to meet their goals – either enhancement/optimisation of 
percutaneous absorption, for example, in the case of pharmaceutical applications, or 
reduction of absorption into the physiologically active tissue in the case of cosmetic purposes 
(Moss et al. 2015). Formulations may include penetration retardants to discourage skin 
permeation, especially, to combat xenobiotic-related toxicity issues (Kaushik et al.  2008), 
or penetration enhancers to elevate drug permeation (Borrás-Blasco et al.  1997; Javadzadeh 
et al. 2010) and hence, to optimise transdermal drug delivery. Formulation selection can also 
enhance drug penetration through skin hydration and occlusion. For example, ointment and 
waxes are generally known to increase hydration through occlusion. However, the 
permeation profiles of drugs from different formulations can be significantly different. One 
example is the permeation of benzoic acid, caffeine and testosterone from three different 
vehicles (ethylene glycol, petroleum and an aqueous gel) through the skin (Moss et al.  2015). 
With regards to penetration enhancers, a number of excipients have been reported to have 
skin penetration enhancement effects. Examples include terpenes (Kang et al.  2007), fatty 
acid esters (Casiraghi et al. 2012), pluronic gels (Escobar-Chávez et al. 2005), cinnamic acid, 
cinnamic alcohol, cinnamaldehyde (Zhang et al. 2007), cyclodextrins (Sinha et al.  2003) and 
liposomes (Bouwstra & Honeywell-Nguyen 2002). One group of compounds that are known 
to have an effect on skin penetration are surfactants. They are known to intercalate with the 
continuous lipid domain of the stratum corneum, thus enhancing fluidity. The effects of 
surfactants on skin permeation have been investigated using a wide range of compounds. 
Surfactants have also been used in conjunction with physical penetration enhancement 
techniques such as iontophoresis to enhance transdermal drug delivery (Silva et al.  2012).  
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1.6 Surfactants 
 ‘Surfactant’ is a diminutive form of ‘Surface Active Agent’. Many pharmaceutical, 
cosmetic and agro-chemical formulations contain surfactants where they are used as an 
emulsifier, or as a suspending, solubilising, wetting and stabilising agent (Borrás-Blasco et 
al.  1997). More importantly, recent years have seen a widespread use of surfactants as 
penetration enhancers to increase drug permeation through skin. The effects of surfactants on 
the skin is determined by their interactions with the skin –  binding with the surface proteins, 
denaturing the surface proteins, solubilising the lipid bilayers, penetration through the lipid 
domain, and interaction with the living cells (Mohd. Yasir et al.  2012). The effects of 
surfactants can lead to an alteration in skin permeability. Many studies suggest an apparent 
concentration-dependent biphasic action of surfactant on skin permeability, such that skin 
permeability increases at low surfactant concentrations but decreases at higher values, usually 
above the critical micelle concentration (CMC). CMC is known as a narrow range of 
concentrations upon reaching which surfactant molecules form micelles (Walters et al.  
1993). At concentrations below the CMC, surfactant exists as monomers and/or premicelles 
(Cui et al.  2008). Any surfactant-driven increase in skin permeability at these concentrations 
(i.e. below the CMC) is generally attributed to the ability of the monomers to penetrate the 
skin lipid domain and to increase its fluidity, thus disrupting the skin barrier function. At or 
above the CMC, a high level of solubilisation of penetrants into the micelles occurs, and this 
decreases the thermodynamic activity of the penetrants and hence, their permeation through 
the skin (Walters et al.  1993). 
Surfactants are amphipathic molecules consisting of a hydrophilic (or polar) head 
group attached to a hydrophobic tail, which is a straight or branched hydrocarbon or 
fluorocarbon chain with 8 – 18 carbon atoms. The molecular weights of surfactants range 
from low to moderate. The uniqueness of their properties is evident in the fact that they tend 
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to concentrate at interfaces and reduce interfacial tension (Mohd. Yasir et al.  2012). The 
interfaces could be between solid/liquid, liquid/liquid, or gas/liquid pairs of phases. 
Surfactants can be well-differentiated from other compounds by two important properties – 
1) adsorption at the surface, and 2) formation of micelles in solution (Porter 1994) (Fig. 1.3).  
 
 
 
 
 
 
Fig. 1.3: Surfactant adsorption and micelle formation (Alexandrova 2007). 
 
Micelles aggregate in a way that the hydrophobic tails are aligned towards the centre 
of the micelles, and the hydrophilic polar heads towards the aqueous bulk phase. To put 
simply, a micelle can be thought of as having two regions – a hydrophilic or polar region and 
a hydrophobic core. Compounds with predominantly lipophilic properties tend to partition 
into the hydrophobic core in a process called solubilisation (Walters et al.  1993), whereas 
hydrophilic or polar compounds prefer to stay in the aqueous bulk phase. 
 
Surfactants are classified into four categories (Mohd. Yasir et al.  2012), based on the 
nature of their polar head groups: 
 Anionic surfactant 
 Cationic surfactant 
 Zwitterionic or amphoteric surfactant 
 Non-ionic surfactant 
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Anionic surfactants carry a negative charge in their head groups. Examples of this 
class include carboxylates (e.g. alkyl carboxylate-fatty acid salts), sulphonates (e.g. alkyl 
benzene sulphonates), phosphate esters (e.g. alkyl ether phosphates) and sulphates (e.g. 
sodium dodecyl sulphate). The penetration enhancement effects of anionic surfactants are 
associated with their ability to penetrate the skin and interact with keratin protein in the 
corneocytes, and the lipid bilayers. The interactions with keratin result in the unfolding of its 
coiled structure thus increasing the water binding sites, and hence enhancing skin hydration. 
The interactions with lipid bilayers induce a structural disorder of the lipid domain of the 
skin. Such disordering increases the fluidity of the stratum corneum, and therefore skin 
permeability (Mohd. Yasir et al.  2012). Several studies reported skin penetration 
enhancement effects of anionic surfactants, both in vitro and in vivo. In one study, sodium 
dodecyl sulphate (SDS) was found to increase the permeation of an antiviral agent, foscarnet, 
through rat skin (Piret et al.  2000). SDS has also been reported to enhance in vitro skin 
permeation of diazepam (Shokri et al.  2001) and lorazepam (Nokhodchi et al.  2003). 
Kitagawa and Ikarashi reported an increase in skin permeation of ketotifen induced by the 
presence of SDS (Kitagawa & Ikarashi 2003). Yamato et al. observed a higher skin 
permeation of propofol, both in vitro and in vivo, with the combined use of SDS and 
propylene glycol in the formulation (Yamato et al. 2009). SDS treatment of murine skin 
resulted in an enhancement of the transdermal permeation of polyethylene glycol (Tsai et al.  
2003).   
Unlike anionic surfactants, cationic surfactants contain a positive charge in their head 
groups. Most of the surfactants of this category correspond to nitrogenous compounds such 
as quaternary ammoniums and fatty amine salts. Examples of cationic surfactants include 
cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BZK) and cetrimide. 
Cationic surfactants are more damaging to the skin than anionic surfactants (Walker & Smith 
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1996). They alter skin permeability mainly by disrupting keratin fibrils of the skin 
corneocytes. The disruption results in the swelling of the stratum corneum and a subsequent 
increase in skin permeability (Mohd. Yasir et al.  2012). The cationic surfactant n-
dodecyltrimethylammonium bromide has been reported to enhance drug permeation across 
skin (Kitagawa & Ikarashi 2003). Shokri et al. found that both benzalkonium chloride and 
CTAB  induced a higher flux of diazepam through rat skin (Shokri et al.  2001). These two 
surfactants have also been reported to increase the percutaneous absorption of lorazepam 
(Nokhodchi et al.  2003).     
Zwitterionic surfactants exhibit both cationic and anionic dissociations. The polar 
head groups of these surfactants contain a quaternary amine group and a carboxyl or sulfonic 
group. Examples are CHAPS, phospholipids (phosphatidylethanolamine, 
phosphatidylcholine), dodecylbetaine and hexadecylbetaine, and amino acids. Zwitterionic 
surfactants enhance skin permeability through the solubilisation of the stratum corneum 
lipids (Mohd. Yasir et al.  2012). Ridout et al. examined the effect of dodecylbetaine and 
hexadecylbetaine on the permeation of nicotinamide across excised skin and found an 
increment in nicotinamide flux owing to the presence of these surfactants (Ridout et al.  
1991). CHAPS has been reported to increase the flux of mannitol through Caco-2 cells, an in 
vitro model of the intestinal mucosa (Nerurker et al.  1996).    
Finally, non-ionic surfactants do not ionise in aqueous solution. Their head groups do 
not carry any charge and are of non-dissociable types, for example, alcohol, phenol, ester, 
amide and ether. Examples of non-ionic surfactants include Tween 80, polyoxyethylenes-2-
oleyl ether, polysorbates, Span 20, poloxamer and Brij 35 (Shin et al.  2001). Non-ionic 
surfactants are less of an irritant than other surfactants and are most frequently used in drug 
delivery applications (Mohd. Yasir et al.  2012). Literature suggests that non-ionic surfactants 
enhance skin permeability by disrupting the intercellular lipids and/or keratin filaments of 
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the corneocytes (Nokhodchi et al.  2003). Limpongsa and Umprayn found Tween 80 to 
increase the skin permeation of diltiazem hydrochloride by three fold (Limpongsa & 
Umprayn 2008). Brij 35 has been reported to enhance the permeation of atenolol (Mohd. 
Yasir et al.  2012).    
 From the above discussion, it is clear that surfactants have widely been studied as 
penetration enhancers using both human and animal skin. However, the effects of surfactants 
on permeation have also been studied using artificial membranes such as polyethersulfone 
(PES) and polydimethylsiloxane (PDMS) membranes. Rahimpour et al. investigated the 
effects of CTAB, SDS and Triton X-100 on the flux of pure water and milk across PES 
membrane (Rahimpour et al.  2007). They observed an increase in water and milk flux, which 
they attributed to the surfactant-induced porosity of the membrane. Another study found 
Tween 80 to enhance water flux through PES membrane (Amirilargani et al.  2009). Waters 
et al. investigated the effects of two surfactants, namely, SDS and Brij 35, on the permeation 
of methylparaben and ethylparaben through PDMS membrane, and found a reduction in 
paraben permeation by SDS, whereas no significant effect was observed with Brij 35 (Waters 
et al.  2013).    
 
1.7 In vitro drug diffusion  
 The assessment of skin permeation of drugs or other penetrants is vital for several 
reasons such as: 
 Estimation of the potential of transdermal drug delivery  
 Risk assessment of the contact of toxic substances with skin (Ottaviani et al.  2006) 
 Measurement of the percutaneous absorption of materials used in cosmetics 
 Risk assessment of the occupational exposure of materials used in several industries 
(Moss et al.  2015) 
 
15 
There are a number of ways skin permeation can be measured or predicted such as in 
vivo (Pillai & Panchagnula 2003; Rosado et al.  2003; Godin & Touitou 2007), ex vivo 
(Schwingel et al.  2008; Minghetti et al.  2000), in situ (Plessis et al.  2001) and in vitro 
(Padula et al.  2008; Kwon et al.  2012; Fang et al.  2001) methods. Schwingel et al. used an 
ex vivo technique to measure the skin permeation of 3-O-methylquercetin, a potential 
antiviral flavonoid (Schwingel et al.  2008). In one study the skin permeability of doxylamine 
was investigated using both in vitro and in situ methods, and a good correlation was found 
between the two techniques within a specific period of time (Plessis et al.  2001). However, 
amongst all of the above-mentioned methods, in vitro and in vivo systems have been 
extensively used in skin permeation research.  
In vivo techniques have been reported to provide useful information about the 
mechanism of skin permeation. They are generally non-invasive in a sense that skin 
responses, such as vasodilatation or skin blanching, are assessed in these techniques, rather 
than measuring blood samples or punch biopsies for subsequent analysis. However, they are 
limited in their applicability to those chemicals that do not produce any non-invasively 
quantifiable physiological changes. Moreover, the non-invasive monitoring of certain 
chemicals, such as those in cosmetics, does not provide any indication of cutaneous toxicity. 
In vivo methods are suitable, particularly, if the compound to be examined is an established 
material (such as ibuprofen), and its ADME (absorption, distribution, metabolism and 
elimination) are measured by analysing bodily fluids (Moss et al.  2015). Nevertheless, it can 
be significantly difficult to perform such experiments for a number of penetrants not only for 
toxicological aspects but also for logistical reasons, for example, the consistent availability 
of volunteers (Ansari et al.  2006). In addition to human volunteers, animals are also used to 
analyse skin permeation in vivo. However, a growing concern against animal testing and a 
ban on animal-tested cosmetics in the EU since 2013 has led researchers to alternative 
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approaches (Adler et al.  2011). Overall, because of the limits of in vivo methods in terms of 
feasibility, availability, or ethical concerns, in vitro techniques are being increasingly 
accepted. 
In vitro techniques are often used prior to in vivo tests and in some instances, for 
example, the evaluation of new compound, are solely used to assess the potential toxicity to 
the human body. Consequently, in vitro models find a widespread application in the 
assessment of the risks and hazards associated with the skin exposure of exogenous 
chemicals. The vast majority of mathematical models have been developed based on the data 
obtained from in vitro experiments using excised human skin. In vitro methods for assessing 
percutaneous absorption are numerous and different in the details of their experimental 
protocols. The diversity of such methods is based on the selection of the diffusion membrane, 
nature of the experiments (e.g. occlusion, duration), type of diffusion cell (i.e. static or flow-
through cells) and the composition of the donor, or receptor phases that are placed either side 
of the diffusion membrane (Moss et al.  2015). The temperature at which an in vitro 
permeation study is performed can also be varied. The majority of the published experiments 
were conducted at either 32 or 37 °C. However, a number of studies were also conducted at 
temperatures of 31-32, 22-30 and 25-31 °C (Moss et al.  2009).    
The aim of an in vitro skin permeation study is to measure the amount of permeant 
that penetrates into and across skin. For this purpose, a diffusion apparatus is used which has 
two chambers – a donor chamber and a receptor chamber – separated by a membrane 
(generally human or animal skin, or artificial). The formulation containing the permeant of 
interest is introduced in the donor chamber at the start of an experiment. The receptor 
chamber is the chamber which is exposed to the membrane, and into which the permeant may 
diffuse, following transport into and across the membrane. A viable diffusion gradient must 
be maintained between donor and receptor solution to avoid equilibrium between both 
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chambers (Moss et al.  2015). The receptor chamber usually has a sampling port from which 
aliquots of samples are collected at pre-determined time intervals for quantification. 
Permeation across the membrane is generally measured by monitoring the rate of compound 
permeation into the receptor chamber, or the rate of compound loss from the donor chamber 
(Ottaviani et al.  2006). 
There are two major types of diffusion cells: static and flow-through cells (Fig. 1.4). 
The static diffusion cells are commonly known as Franz cells (Franz 1975). In a Franz cell, 
the permeant penetrates into a “static” receptor chamber of a fixed volume that is kept at a 
controlled temperature and is continuously stirred to ensure homogenous mixing of the 
receptor solution throughout an experiment and to avoid any “dead” zones or diffusion 
gradients within the receptor chamber. Franz-type permeation cells can be found in a range 
of designs and sizes. These cells are upright and hence allow a range of pharmaceutic or 
cosmetic formulations such as solutions, creams or ointments to be investigated. One of the 
main limitations of Franz-type diffusion cells is the associated issue of “sink conditions”. In 
a static permeation cell, the concentration of penetrant in the receptor chamber needs to be 
no greater than 10 % of its saturated solution (Anissimov & Roberts 1999). An alternative 
way of solving issues related with “sink conditions” is to use flow-through type diffusion 
cells. Flow-through cells are also known as “Bronaugh” cells. In a flow-through diffusion 
cell, the receptor solution is continuously pumped through tubing that supplies a small 
compartment beneath the membrane and is collected into a receptacle for analysis, either 
offline or online. The advantage of a flow-through system is that the receptor phase does not 
have to be replaced, even for a permeant that rapidly penetrates. Despite the flexibility of 
flow-through cells, these cells are more complex and significantly more expensive than static 
Franz cells. The other commonly used diffusion cell is a side-by-side diffusion cell, which 
has the advantage of stirring and mixing in both donor and receiver chambers, but is limited 
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by the fact that a number of formulations can be difficult to apply in this system (Moss et al.  
2015).       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Examples of major types of diffusion cells (PermeGear 2015)     
 
In in vitro skin permeation studies, the donor phases generally involve aqueous or 
water-ethanol solvents. Other organic solvents such as propylene glycol may also be used to 
facilitate drug delivery across the skin. The majority of the receptor phases are based on 
buffer solutions, usually phosphate buffers with a pH of 7.4 (Moss et al.  2015). The receptor 
solution may also contain solubilising agents including various surfactants and proteins (e.g. 
bovine serum albumin). It is clear that there are significant variations in the composition of 
 
19 
formulations (donor or receptor solutions), yet only a few studies have considered 
formulation matters (Pugh et al.  2005; Ghafourian et al.  2010). In particular, ionisation of 
compound is not generally taken into consideration when modelling percutaneous absorption. 
The widely used membrane in the assessment of in vitro skin permeation is human 
skin (Franz 1975). Skin from several animal species such as pigs, rats, snakes, monkeys and 
guinea pigs are also commonly used as a human skin replacement (Roberts & Mueller 1990; 
Barbero & Frasch 2009). Amongst animal skins, pig and rat skins have found widespread 
use, with the former being similar to the diffusion characteristics of human skin and hence a 
better surrogate for transdermal studies. Rat or mouse skin is more permeable (up to 10 times) 
than human skin (Roberts & Mueller 1990). However, rodent skin is also very popular, 
possibly because of its predominant use in pharmacological research. LSEs (living skin 
equivalents) have also been reported when studying in vitro skin permeation (Hager et al.  
1994). Nevertheless, LSEs have so far failed to find widespread use, mainly because of the 
cost, reproducibility issues and their lack of robustness compared with human or animal skin. 
Moreover, they are generally known to overestimate the permeation rate through human skin 
(Moss et al.  2015). Studies have also reported the use of natural membranes such as egg, 
tomato, peach and onion membranes as skin mimics. One study compared the in vitro 
permeation of diclofenac across onion membrane and human skin, and found no significant 
difference in permeation (p > 0.93) (Ansari et al.  2006). However, these natural membranes 
are very limited in terms of applicability and robustness.  
Human skin, usually excised, is the gold standard for in vitro drug diffusion studies, 
yet the use of excised skin is not without problems. Human skin is generally obtained from 
skin banks or tissue donors where surgical procedures including amputations are used to 
remove the skin. Surgical procedures for removing the skin may involve the use of alcohol-
based disinfectants, which can compromise the barrier integrity of the skin and hence the skin 
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permeability. Therefore, the experimenter of in vitro permeation study has little control over 
the handling and quality of the skin. Moreover, the skin may be kept frozen prior to dispatch 
for use in experiments, and this can possibly cause the damage or degradation to the 
membrane (Moss et al.  2015). Furthermore, human or animal skin can be difficult to obtain, 
and there can be variation in skin permeability because of age, sex, race and anatomical site 
(Ansari et al.  2006). The above-mentioned difficulties and limitations of using mammalian 
skin have led researchers to consider artificial (or synthetic) membranes as in vitro skin 
mimics. Synthetic membranes are very useful when a large number of experiments, in 
particular, preformulation screening studies, need to be carried out (Moss et al.  2015).     
 
1.8 Synthetic membranes as skin mimics 
 Synthetic membranes are composed of polymeric macromolecules, generally 
compacted in layers. They can be prepared using synthetic polymers (such as polysulfone or 
polycarbonate) or semi-synthetic polymer (such as cellulose acetate or regenerated cellulose 
etc.). Synthetic membranes have found their extensive applications, mainly, in industrial 
separation processes such as gas separation, pervaporation, reverse osmosis, electrodialysis, 
microfiltration and ultrafiltration (Ng et al.  2012). For in vitro drug diffusion studies, 
synthetic membranes are utilised, as mentioned earlier, to reduce the variation in skin 
permeability or when biological skins are not available. Numerous studies have considered 
the use of synthetic membranes to study drug diffusion in vitro (Parks et al.  1997; Feldstein 
et al.  1998; Iordanskii et al.  2000; Wasdo et al.  2008; Sugibayashi et al.  2010; Ng et al.  
2010). Synthetic membranes for in vitro drug diffusion experiments are intended mainly for 
two purposes – either to simulate the skin, or to assess the quality of drug products. In 1989, 
Shah and co-researchers from the FDA demonstrated that synthetic membranes, along with 
Franz diffusion cells can be used for the quality assessment of semi-solid products (Shah et 
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al.  1989). Unlike skin simulation, synthetic membranes for quality assessment purposes 
should not be rate-limiting, and should only provide a means for separating the donor and 
receptor phases (Ng et al.  2012). Examples of synthetic membranes used for in vitro 
permeation studies include pure cellulose, cellulose acetate, cellulose ester, cellulose nitrate, 
carbosil (Feldstein et al.  1998), Celgard 3500, polycarbonate, polypropylene, polysulfone 
and silicone membranes (Ng et al.  2012). One study investigated the permeation of ibuprofen 
across a total of 14 synthetic membranes, namely, cellulose nitrate, Nuclepore, Celgard, 
Cyclopore, Tuffryn, Supor, AN69, cellulose ester, Biodyne B, Biodyne C, Cuprophan, 
benzoylated cellulose, Visking and PDMS membranes (Ng et al.  2010). The study suggested 
that when selecting a synthetic membrane, it would be important to consider the compatibility 
of the membrane with the donor and receptor solution, and the cost effectiveness of the 
membrane. 
 Synthetic membranes employed in in vitro drug diffusion studies can be broadly 
divided into two categories – cellulose-based and polymeric-based membranes. Cellulose- 
based membranes are made of regenerated cellulose and its derivatives, whereas polymer-
based membranes are composed of non-cellulose polymers such as polysulfone, 
polycarbonates and polydimethylsiloxane (PDMS). The synthetic membranes used for 
topical formulation assessment are generally based on regenerated cellulose (Reid et al.  
2008; Ng et al.  2012). Cellulose ester and polysulfone membranes are also used in the 
assessment of topical drug products (Shah et al.  1989; Wu et al.  1992). The common feature 
of the membranes used for topical formulation assessment is that they contain pores. 
Therefore, these membranes do not offer rate-limiting permeation properties, which are 
necessary, should the membranes be used to simulate human skin. One type of synthetic 
membrane that has a skin-like rate-limiting barrier property is PDMS membrane, commonly 
known as silicone membrane. Silicone membrane has been extensively used in vitro to 
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estimate or predict the skin permeability of drugs or cosmetic ingredients (McCarley & 
Bunge 2003; Ley & Bunge 2007; Santos et al.  2009; Oliveira et al.  2010; Santos et al.  2011; 
Oliveira et al.  2012).  
 
1.9 Polydimethylsiloxane membrane 
 Polydimethylsiloxane (PDMS) (Fig. 1.5) membrane is a non-porous, amorphous and 
hydrophobic elastomer (Twist & Zatz 1986). The siloxane bond (-Si-O-Si-) that forms the 
backbone of the membrane is very highly stable. PDMS membrane can be immersed into 
water for a long period, with no effect on its mechanical strength or physicochemical 
properties. The physiological and chemical inertness of PDMS membrane broadened its 
applications in a number of fields including medical, electronic, automotive and aerospace 
industries (Simon et al.  2008). In particular, PDMS has found its widespread use in the 
fabrication of microfluidic devices, mainly because of its incredible properties such as gas 
permeability, transparency and ease of patterning with soft lithography. PDMS-containing 
microfluidic devices are used for several purposes including electrophoresis, long-term 
organotypic culture and cell culture  (Markov et al.  2014).  
 
 
 
Fig. 1.5: Chemical structure of polydimethylsiloxane (Glombitza & Muller-Goymann 
2001)  
 The non-porous nature of PDMS membrane made it suitable for the selective 
permeation of liquids and gases, and thus the membrane is used for water desalination, the 
separation of gases from liquids and many other purposes. Amongst many synthetic 
membranes, PDMS has shown excellent analytical performance for the fast and efficient 
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permeation of a range of volatile organic compounds (VOCs), with an exception to polar 
compounds such as alcohols (Boscaini et al.  2004). Moreover, PDMS membrane is widely 
used in in vitro drug diffusion studies to simulate the skin. The suitability of PDMS to predict 
drug permeation is generally attributed to the skin-analogous hydrophobicity and rate-
limiting properties of the membrane. Drug permeation through PDMS membrane can be 
explained using a solution-diffusion model. According to this model, drug molecules first 
dissolve in the membrane and diffuse across the membrane down a concentration gradient. 
In this model, the steady-state flux (J) of drug is based on Fick’s law of diffusion (Eq. 1.1) 
(Ng et al.  2012)   
𝐽 =  
D . K . CV
h
                                                           (1.1) 
where, K is the partition coefficient of drug between the vehicle and the membrane, D is the 
diffusion coefficient of drug into the vehicle that fills in the membrane pores, Cv is drug 
solubility in the vehicle, and h is the membrane thickness. To permeate across a non-porous 
membrane, such as PDMS, drug molecules traverse through the tiny gaps between the 
polymer chains of the membrane, which generally results from the thermal motion of the 
polymer molecules (Ng et al.  2012).  
A large number of studies have been performed on PDMS membrane, either to 
compare drug permeability profiles with an in vivo situation (Woolfson et al.  1998) or human 
skin in vitro (Romonchuk & Bunge 2006), or to establish QSPR (Quantitative Structure-
Permeation Relationship) models (Geinoz et al.  2002), or to search for factors affecting drug 
permeation (Oliveira et al.  2010; Dias et al.  2007; Santos et al.  2011). Romonchuk and 
Bunge studied the permeation of two compounds, 4-cyanophenol and methyl paraben, from 
pure powder and saturated aqueous solution through human skin and PDMS membrane 
(Romonchuk & Bunge 2006). They found a faster permeation for both of the model 
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compounds across PDMS compared with the skin. Wasdo et al. found correlations (r2 = 
0.743) between hairless mouse skin and PDMS membrane for the permeation of 32 
compounds from water (Wasdo et al.  2009). Woolfson et al. examined the permeation of 
tetracaine (a local anaesthetic agent) from a range of formulations through PDMS membrane, 
and found good in vivo correlations in cases where the lipophilicity of the permeant was the 
prime factor for drug permeation (Woolfson et al.  1998). With regards to a QSPR model, a 
major study for quantifying permeability across PDMS membrane was carried out by Chen 
et al. (Chen et al.  1996) where they developed a model (Eq. 1.2) using the permeation data 
of 103 compounds.  
log  𝐽mss = − 2.497 − 4.339 ∑ 𝑒+ − 1.531 ∑ 𝑒− + 4.065 (∑ 𝑒+ . ∑ 𝑒𝑝−)
+ 0.649 log 𝐶𝑠 − 0.00651 MW − 0.640 imidazole + 0.689 amine 
[𝑛 = 103    𝑟2 = 0.966   𝑠 = 0.238   𝐹 = 386.5]    (1.2) 
 where 
𝐽mss is the maximum steady-state flux (µ mol/s/cm
2); 
∑ 𝑒+ is the sum of the charge values of hydrogen atoms with charge higher than 0.1 
and the positive charge of a nitrogen atom in a nitro group; 
∑ 𝑒− is the sum of the absolute charge values of all other heteroatoms with unshared 
electron pairs in the same molecule; 
𝐶𝑆 is the solubility; 
MW is the molecular weight (g/mol); and 
Imidazole and amine are indicator variables for imidazole and aliphatic amine groups.  
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Using the data published by Chen et al. (1996), Agatonovic-Kustrin et al. developed a novel 
artificial neural network model, which indicated that molecular shape and size, hydrogen-
bonding capacity of drugs, intermolecular interactions and conformational stability were 
important for drug penetration across PDMS membrane (Agatonovic-Kustrin et al.  2001). 
Several studies have reported that drug permeation through PDMS membrane can be 
affected by a number of factors including vehicles, temperature and the physicochemical 
properties of the drug itself. Oliveira et al. studied the permeation of methyl paraben in the 
presence of butanol and heptanol across PDMS membrane at different temperatures, and 
found an enhancement of paraben permeation owing to both the vehicles and temperature 
(Oliveira et al.  2010). Dias et al. investigated the role of several solvents on the permeation 
of three model compounds, namely, caffeine, salicylic acid and benzoic acid, across silicone 
membrane, and suggested that the drug diffusion process was influenced by both the 
membrane-solvent interactions and solute characteristics such as size, shape and charge 
distribution (Dias et al.  2007). Two other factors that can affect permeation through PDMS 
membrane (though have only been studied to a limited extent), are ionisation (Smith & Irwin 
2000) and surfactants (Waters et al.  2013). 
 One of the attractive features of PDMS-based materials is that their surface properties 
can be altered using a range of chemicals (Roman & Culbertson 2006), or physical treatment 
techniques (Markov et al.  2014). In particular, the surfaces of PDMS-based materials can be 
transformed from hydrophobic to hydrophilic, and then additional functional groups can be 
added to the modified surface to customise it for various applications, for example, making 
the materials more suitable for separation purposes. Several methods are utilised for the 
modification of PDMS surface, with each method having its own specifications, and purposes 
such as improving electroosmotic flow, making the membrane surface more hydrophilic and 
resistant to chemical absorption or adsorption (Roman & Culbertson 2006).  
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1.10 Methods for the modification of PDMS surface  
 PDMS surfaces can be modified by a number of methods. The purposes of such 
modifications range from improving the performance of PDMS-based microfluidic devices 
to optimising gas permeability through PDMS membrane. Various surface modification 
techniques can be found in literature:  
i. Generally, plasma discharge and/or UV radiation are used to oxidise PDMS surfaces. 
Such treatments result in the surface silane (Si-CH3) groups of the membrane being 
replaced with silanol (Si-OH) groups, thus introducing hydrophilicity to the 
membrane surface (Sui et al.  2005). The silanol groups of the PDMS surface can 
then be used to attach a variety of functional groups using simple silanisation or free 
radical chemistry. For example, acrylamide can be attached onto the oxidised PDMS 
surface through a silanisation process. (Roman & Culbertson 2006). Polyethylene 
glycol (PFG) can also be attached onto the modified PDMS surface. The resulting 
PEG-grafted surface is relatively stable and shows protein-propelling characteristics, 
which is required for the development of microfluidic-based biosensing devices 
(Papra et al.  2001). 
ii. Covalent surface modification techniques involve the use of chemicals such as cerium 
and nitric acid to oxidise the PDMS surface. This technique does not use coronal 
discharge or plasma (Roman & Culbertson 2006). The oxidised PDMS surface can 
then be used for the attachment of acrylamide, which offers a reproducible and stable 
coating of the microfluidic device allowing highly efficient peptide separation (Slentz 
et al.  2002). Covalent surface modification can also be achieved, for example, in 
assembled PDMS channels, using graft photo-polymerisation. However, the 
requirement of multiple washings of the channels makes the procedure lengthier 
(Bauer et al.  2010). 
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iii. Non-covalent methods involve the use of proteins, ionic surfactants and 
polyelectrolyte layers (Roman & Culbertson 2006). For example, Badal et al. used 
SDS and CTAB solutions in PDMS-coated microchip devices to control 
electroosmotic flow (EOF) (Youssouf Badal et al.  2002). Yang et al. used a protein-
bound phospholipid bilayer-coated PDMS microchannel for a rapid immunoassay 
(Yang et al.  2001). Polyelectrolyte layers are used to increase, decrease, or reverse 
the EOF (Roman et al.  2005).   
iv. Chemical vapour deposition (CVD) methods are used to coat the luminal surfaces of 
PDMS-based lab-on-a-chip devices with thin polymer films such as poly (p-xylene 
carboxylic acid pentafluorophenolester-co-p-xylene) (PPX-PPF) and poly (p-xylene-
2,3-dicarboxylic acid anhydride). Such coatings are used to immobilise protein in 
PDMS-based microfluidic devices, and to screen pharmacologically active 
compounds in cell-based assays (Lahann et al.  2003). 
v. Sol-gel methods are generally used to modify cured PDMS surfaces. In these 
methods, inorganic compounds, for example, silica and the oxides of titanium, 
zirconium, aluminium and germanium, are imbedded within the PDMS surface. Sol-
gel techniques are suitable for rapid and efficient inorganic coatings, which increase 
the separation efficiencies of PDMS-based microfluidic devices (Roman & 
Culbertson 2006).  
               
The above-mentioned methods for PDMS surface modification have predominantly 
been used or studied with regards to PDMS-based microfluidic devices. Among these 
methods, plasma surface treatment has been accepted as an easy, economic and reliable 
technique. In some cases, plasma treatment acts as a first stage in a series of procedures to 
modify the PDMS surface (Yu et al.  2015). The purposes of modifying PDMS membrane 
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surface by plasma treatment have been limited – either to induce grafted polymerisation (Lee 
et al.  1996), investigate gas permeability (Markov et al.  2014), or analyse surface properties 
such as wettability (Bodas et al.  2008). 
       
1.11 Plasma surface treatment  
 ‘Plasma’ is regarded as the fourth state of matter. Plasma is generated when gases are 
excited by radio frequency (rf), microwave or electrons from a hot filament discharge. It 
contains highly excited gas atoms and molecules, ions, electrons, UV radiation, neutral gas 
atoms and molecules, and radical species. The high density of excited and ionised species of 
plasma can interact and alter material surfaces placed in contact with plasma. Plasma 
treatment can incorporate different functional groups on polymer surfaces. Examples include 
carboxyl, hydroxyl, hydroperoxide, carbonyl and amino groups (Tu et al.  2005). Plasma 
surface treatment is performed in an evacuated chamber. After pumping the air out from the 
chamber, a gas or mixture of gases is allowed to flow in at low pressure. Energy in the form 
of electrical power is then applied through the gas, and plasma is generated. The energy is 
produced and provided by an excitation source, known as a plasma source (Fig. 1.6). Active 
oxygen species and UV radiation from plasma break up the separating agents, impurities and 
oils from sample surface. These are pumped away by a vacuum system. Activated oxygen 
species (radicals) from plasma react and bind with the active surface sites all over the sample 
material, producing a highly chemically reactive surface.   
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Fig. 1.6: Schematic diagram of a plasma source (Chu et al.  2002) 
 
Through plasma surface treatment, it is possible to change the compositions and 
properties of a polymer such as wettability, chemical inertness, metal adhesion and 
biocompatibility. Consequently, plasma-based techniques have found extensive and diverse 
applications, mainly, in the biomedical field, for example, to treat surgical instruments and 
venous catheters to improve friction and biocompatibility (Chu et al.  2002). For biomedical, 
biotechnological and bio-diagnostic applications, plasma-based approaches are utilised in 
several strategies: 
i. Biologically active molecules, such as proteins, are immobilised on plasma-
fabricated surfaces through conventional chemical reaction. 
ii. Protective surfaces or coatings are created to control bio-interfacial interactions. 
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iii. Non-reactive surfaces are produced that do not possess attractive interfacial forces 
toward proteins and thus have non-fouling properties (Siow et al.  2015). 
 
 Plasma treatment can be of various types depending on the choice of gas or mixture 
of gases. Below are the few examples that have been reported in literature: 
 Air plasma (Volkov et al.  2015) 
 Nitrogen-based plasma such as N2, NH3 (Kull et al.  2005; Lai et al.  2008; Pang et 
al.  2012)  
 Ar-plasma (Lee et al.  1996)  
 O2 plasma (Kim et al.  2002; Sartowska et al.  2003; Bodas et al.  2008) 
 H2O plasma (Steen et al.  2002)  
 Acrylic acid plasma (Weibel et al.  2006) 
 Mixed gas-based plasma such as Ar/NH3 (Bryjak et al.  2002; Kull et al.  2005), 
O2/NH3 (Kull et al.  2005), C2H2/N2 (Tu et al.  2005). 
 
It can be seen from these examples that plasma types are diverse, and this diversity 
has enabled plasma treatment to be used for a wide range of purposes. For example, 
Zarshenas et al. utilised corona air plasma for modifying polyamide membrane to improve 
gas separation performance (Zarshenas et al.  2015). H2O and N2 plasmas were used to 
improve antifouling properties of polypropylene membrane (Yu et al.  2008). Weibel et al. 
modified polyurethane membrane using acrylic acid plasma to improve the efficiency for the 
separation of methanol from methyl-t-butyl ether (Weibel et al.  2006). H2O plasma was used 
to increase the wettability of polyethersulfone and polyethylene membranes (Steen et al.  
2002). Nitrogen plasma was used to create a permanent hydrophilic membrane surface (Kull 
et al.  2005). Markov et al. used low pressure air plasma to measure oxygen diffusivity 
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through PDMS membrane to understand normoxic and hypoxic oxygen conditions in 
microfluidic bioreactor systems (Markov et al.  2014).  Despite the extensive research on 
plasma treatment methods for the modification of synthetic membranes, limited research, as 
mentioned in Section 1.10, has focused on such modification with regards to PDMS 
membrane. Moreover, no known study has considered the implication of plasma-modified 
PDMS membranes in in vitro drug diffusion studies, where PDMS membranes are often used 
as skin mimics.          
 
1.12 Aim and objectives 
The research presented in this thesis aims to understand the effect of several factors 
including formulation pH, excipients, and membrane surface modification on drug 
permeation through a chemical based skin mimic, namely silicone membrane. 
The objectives of this research work are presented below: 
1. To study the effect of the ionisation on the permeation of drugs through silicone 
membrane.  
2. To study the effect of surfactants on the permeation of drugs across silicone 
membrane. 
3. To predict the mechanism of surfactant effect on drug permeation through silicone 
membrane. 
4. To investigate the effect of plasma surface modification of silicone membrane on 
the permeation of drugs. 
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Chapter 2: Experimental 
  
2.1 Materials 
Polydimethylsiloxane (PDMS) membrane, with a standard thickness of 130 µm, was 
purchased from ATOS Medical (Hörby, Sweden). The flow-through diffusion cells were 
purchased from PermeGear Inc. (Hellertown, PA 18055 USA). De-ionised water was used 
throughout the experiments. Chemicals used are listed in Table 2.1, along with their 
physicochemical properties (Table 2.2).  
Table 2.1: The purity and supplier of the compounds analysed 
Compound Purity Supplier 
1-methyl-3-phenylpropylamine 98.0 % Sigma-Aldrich 
Benzocaine ≥ 99.0 % Sigma-Aldrich 
Benzoic acid > 99.5 % Sigma-Aldrich 
Benzotriazole 99.0 % Sigma-Aldrich 
Caffeine 97.0 % Sigma-Aldrich 
Ibuprofen > 97.0 % BASF 
Ketoprofen > 98.0 % TCI Europe 
Lidocaine > 98.0 % Sigma-Aldrich 
Sodium dodecyl sulfate ≥ 99.0 % Sigma-Aldrich 
Brij 35 Proteomics grade BDH Laboratory 
CTAB ≥ 98.0 % Sigma-Aldrich 
CHAPS ≥ 98.0 % Fisher Scientific 
Tween 80 Super refined  Croda International  
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Table 2.2: Physicochemical properties of chemicals (Molecular weight, polar surface area 
and log P were generated from ACD/labs, RSC, UK)  
1-methyl-3-phenylpropylamine 
 
Molecular weight 149.23 g/mol 
Polar surface area  26 Å2 
log P 2.18 
pKa (U.S National 
Library of Medicine 
2016) 
9.79 
CAS Number 22374-89-6 
Benzocaine 
 
Molecular weight 165.19 g/mol 
Polar surface area  52 Å2 
log P 1.95 
pKa (DrugBank 2016) 2.78 
CAS Number 94-09-7 
Benzoic acid 
 
Molecular weight 122.12 g/mol 
Polar surface area 37 Å2 
log P 1.89 
pKa (Wang et al.  
2013) 
4.2 
CAS Number 65-85-0 
Benzotriazole 
 
Molecular weight 119.12 g/mol 
Polar surface area 42 Å2 
log P 1.34 
pKa (Benitez et al.  
2015) 
8.2 
CAS Number 95-14-7 
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Caffeine  
 Molecular weight 194.19 g/mol 
Polar surface area 58 Å2 
log P -0.13 
pKa (ACD Lab, RSC) 0.52 
CAS Number 58-08-2 
Ibuprofen 
 
Molecular weight 206.28 g/mol 
Polar surface area 37 Å2 
log P 3.72 
pKa (Willian & 
Pritchett 2014) 
4.9 
CAS Number 15687-27-1 
Ketoprofen  
 
Molecular weight 254.28 g/mol 
Polar surface area 54 Å2 
log P 2.81 
pKa (Bechet 1999) 4.0 
CAS Number 22071-5-4 
Lidocaine 
 
Molecular weight 234.34 g/mol 
Polar surface area 36 Å2 
log P 3.63 
pKa (Liu et al.  2003) 7.8 
CAS Number 137-58-6 
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Sodium Dodecyl Sulphate 
 
Molecular Weight 288.40 g/mol  
Charge Anionic 
CMC 8 mM 
Micellar shape Spherical 
Brij 35 
 
Molecular Weight 1199.54 g/mol 
Charge Non-ionic 
CMC 0.09 mM 
Micellar shape Spherical 
CTAB 
 
Molecular Weight 364.45 g/mol 
Charge Cationic 
CMC 0.82 mM 
Micellar shape Spherical 
CHAPS 
 
Molecular Weight 614.88 g/mol 
Charge Zwitterionic 
CMC 4 mM 
Micellar shape Rod-like 
Tween 80 
 
Molecular Weight 1310 g/mol 
Charge Non-ionic 
CMC 5-50 µM 
Micellar shape Cylindrical  
 
 
 
 
46 
2.2 Methods 
2.2.1 iGC SEA (Inverse gas chromatography – surface energy analyser) methodology 
 70 mg of PDMS membrane was cut into small pieces and packed into an 
individualised iGC silanised glass column. The dispersive surface energy (sD) and the acid-
base free energy (sAB) of adsorption were determined by running the sample at a series of 
surface coverage with alkanes and polar probe molecules. The sample column was pre-
conditioned for 2 hours at 25 °C and 0 % RH with 10 mL/min helium carrier gas. The 
experiment was conducted at 25 °C with 10 mL/min total flow rate of helium, and using 
methane for dead volume correction. The data were analysed using both standard and 
advanced surface energy analysis software (Surface Measurement Systems, UK). 
 
2.2.2 Differential scanning calorimetry (DSC) 
 PDMS membrane was cut to an appropriate size for investigation and treated 
overnight in phosphate buffer (0.02 M PBS, pH 7.4) solution with or without the surfactants 
(SDS, Brij 35, CTAB, CHAPS and Tween 80) present in the buffer at 20 mM. The samples 
were then dried with soft tissue to remove excess liquid. DSC scans of the untreated and the 
treated samples were performed using a DSC 1 (Mettler-Toledo Ltd., Leicester, UK), at a 
heating rate of 1 °C/min over a range of -60 °C to -20 °C. All DSC thermograms were 
assessed with regard to the phase transition of PDMS membrane, which was reported to be -
40 °C (Dias et al.  2007).          
 
2.2.3 Fourier-transform infrared (FTIR) spectroscopy 
 FTIR analysis of the untreated and treated membranes (see Section 2.2.2 for treatment 
procedure) were performed using a Nicolet IR 380 spectrometer. The samples were cut into 
suitable sizes and placed in direct contact with the diamond crystal of the spectrometer. A 
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measurement range of 4000-400 cm-1 was used for all experiments. The data were obtained 
from, and analysed by a spectrometer-linked computer equipped with the Omnic software 
(version 7.2a).  
     
2.2.4 Nuclear magnetic resonance (NMR) spectroscopy 
 SDS and Brij 35 were used to prepare the sample solutions, at concentrations of 4, 6, 
8, 10 and 20 mM for the former, and 1 and 10 mM for the latter. When necessary, membranes 
were kept in the solutions for ~24 h. D2O was used as solvent. In all 
1H NMR experiments, 
samples were analysed using a Bruker AV400 spectrometer (400 MHz) at 25 °C, and the 
spectra were then processed using Bruker TopSpin 3.1 software.    
 
2.2.5 Plasma surface treatment process  
The surface of PDMS membrane was modified using a standard plasma surface 
treatment method. The treatments were performed in a benchtop laboratory plasma unit 
(Henniker Scientific) (Fig. 2.1).  
 
 
 
 
 
 
 
 
 
Fig. 2.1: A benchtop laboratory plasma unit. 
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PDMS membrane pieces were cut with a diffusional area of 0.554 cm2 for flow-
through permeation cells and placed in the plasma unit under low pressure on full power (40 
kHz, 100 W). The same treatment was repeated on the alternate surface of the pieces under 
identical conditions with both surfaces exposed to air plasma for 90 seconds each. Contact 
angle measurement, SEM (Scanning Electron Microscopy), EDX (Energy Dispersive X-ray) 
analysis and permeation studies were conducted using the membrane immediately after the 
plasma treatment.  
For aging studies, the treated PDMS samples were stored under air tight conditions 
for a maximum of 8 weeks, and permeation studies were performed using the stored samples 
aged for 1, 2, 4 and 8 weeks.    
  
2.2.6 Contact angle measurement 
 Contact angle analysis was carried out to examine the alteration of hydrophilicity of 
PDMS membrane before and after the plasma treatment. The static contact angles of the 
treated and untreated PDMS samples were measured at room temperature using a sessile drop 
method. This method employs an optical goniometer with an attached precision syringe 
(FTA1000, Surface Science Instruments, USA). A droplet of deionised water was dispensed 
from the precision syringe onto PDMS surface (treated or untreated) and the resultant angles 
were measured over a period of 200 s.  
 
2.2.7 Scanning electron microscopy (SEM) 
 SEM images of PDMS membrane were obtained on a FEI Quanta 250 equipped with 
backscattering and secondary electron detectors. The membrane samples were affixed to a 
standard aluminium stub by double-sided carbon tape and then sputter-coated with a thin 
layer of Au (gold) to prevent surface charging. After that the samples were loaded in the SEM 
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for imaging. For the study mentioned in Chapter 5, two categories of PDMS samples were 
analysed – untreated and treated (see Section 2.2.2 for treatment procedure). For the study 
mentioned in Chapter 6, three categories of PDMS samples were investigated – untreated, 
plasma-treated, and aged (maximum for 8 weeks) plasma-treated. In all analysis, the 
acceleration voltage was 5 keV. Everhart-Thornley detector (ETD) was used to detect the 
secondary electrons that are ejected from the k-shell of the sample atoms.    
    
  
 
 
 
 
 
 
 
 
 
Fig. 2.2: A FEI Quanta 250 Scanning Electron Microscope. 
  
2.2.8 Energy dispersive X-ray analysis (EDX) 
  EDX analysis of the PDMS membranes, both plasma-treated and aged plasma-
treated, were performed using an Oxford detector attached to a FEI Quanta 250 ESEM. The 
procedure was analogous to that mentioned in Section 2.2.6. 
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2.2.9 Permeation experiments and data analysis 
A system employing flow-through type diffusion cells with a diffusional area of 0.554 
cm2 was used for all permeation studies. PDMS membrane, with a measured thickness of 130 
µm, was employed as a permeability barrier. In all cases, except for plasma-treated samples, 
the membrane was soaked in buffer solution for 30 minutes prior to being mounted in the 
diffusion cells. After assembly the cells were placed on a cell warmer for a temperature of 
32 °C to be maintained. To start each permeation experiment, 0.8 mL of the donor solution 
containing model compound (and/or surfactant) was added to the diffusion cell. In all 
experiments the concentration of the model compounds in the donor solution was 1 mg/mL. 
In the cases whereby surfactants were involved (Chapter 4), the concentrations used were 0, 
4, 8 or 20 mM for SDS, Brij 35, Tween 80, CTAB and 0, 2, 4 or 20 mM for CHAPS. 
Phosphate buffer saline (pH 7.4 for the study discussed in Chapter 4 and 6, and pH 4.5, 6.0, 
6.5, 7.0, 7.4, 8.0 and 8.5 for the study discussed in Chapter 3) was pumped through the cells 
at 5 mL/h. The concentration of PBS used in Chapter 3 and 4 was 0.02 M, whereas for 
Chapter 6 it was 0.05 M. The samples were collected by means of a fraction collector at the 
predetermined time intervals.  
Extracted samples were assayed by means of a validated UV spectroscopic method 
to quantify the model compounds (1-methyl-3-phenylpropylamine at 217 nm, benzocaine at 
258 nm, benzoic acid at 226 nm, benzotriazole at 262 nm, caffeine at 273 nm, ibuprofen at 
230 nm, ketoprofen at 264 and lidocaine at 219 nm). Calibration plots were constructed using 
at least five concentration points for all model compounds and found to be linear (R2 ≥ 0.990) 
in the range of 2-10 µg/mL.   
The steady state flux (𝐽) was determined from the slope of the best-fit linear plot of 
the cumulative amount of the drug permeated per unit area versus time. All values are 
expressed as the mean values of three replicates shown with standard deviation based error 
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limits. Statistical analysis was carried out using Minitab software (version 16). One-way 
ANOVA at 95 % confidence interval level (p ≤ 0.05) was performed to test the significance 
in the values obtained, and post hoc comparison was executed using pairwise Tukey’s test, 
where the difference in means was found to be significant. 
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Chapter 3: Effect of ionisation on the permeation of compounds 
through poly(dimethylsiloxane) membrane 
 
This chapter investigates the role of compound ionisation on their permeation across 
polydimethylsiloxane (PDMS) membrane. Six model compounds were analysed to determine 
the amount permeated across the membrane, each at three specific percentages of ionisation. 
In addition, iGC-SEA (Inverse Gas Chromatography Surface Energy Analyser) was utilised 
to determine the surface chemistry and surface energy profile of the membrane.        
 
3.1 Introduction 
 The permeation of compounds through human skin is a complex process and can be 
difficult to predict using currently established in vitro methods such as mathematical models, 
cultured skin alternatives and artificial membranes (Waters 2015). Despite the limited ability 
of predicting percutaneous absorption, their development and use have gained widespread 
interest among researchers as there is an on-going trend to move away from an animal-based 
testing model in the EU. In particular, artificial membranes have found extensive application 
in early-stage assessment of percutaneous absorption (Moss et al.  2015). Analytical 
techniques using artificial membranes are mainly concerned with the use of polymeric 
materials such as polydimethylsiloxane (PDMS) membrane, generally known as silicone 
membrane (Oshima et al.  2012). PDMS is a commonly used polymer that has a wide range 
of industrial applications, for example, liquid and gas separation (Li et al.  2013; Alexander 
Stern 1994), pervaporation (Dong et al.  2014) and microfluidic devices (Fan et al.  2015). 
In pharmaceutical analysis, PDMS membrane is used to mimic human stratum corneum (the 
outermost layer of skin) in a system incorporating a donor solution and receptor solution, the 
latter from which samples are taken routinely for analysis to quantify the rate and extent of 
compound permeation within a pre-determined period of time (Sloan et al.  2013). Such data 
are useful to predict the fate of compounds following their application on to the skin surface 
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which is crucial for toxicological assessment and formulation development. Studies based on 
these in vitro predictive methods use diffusion apparatus known as Franz cells and are 
routinely carried out for analysing pharmaceutical, cosmetic and household products (Baert 
et al.  2010; Bartosova & Bajgar 2012). PDMS membranes are favourable (Zhu et al.  2010) 
amongst researchers for a number of reasons, for example, simplicity of their use, 
reproducibility of their composition and thickness, and cost effectiveness (Ng et al.  2012). 
Moreover, PDMS membrane has been reported to show good correlation with the in vivo 
situation in the case where the penetrant lipophilicity is the prime determinant of compound 
permeation across the membrane (Moss et al.  2015). The hydrophobic nature of the 
membrane creates a barrier effect, as is seen in vivo and provided that certain conditions are 
met, i.e. permeation is via passive diffusion, the penetrant is metabolically inert and no 
permeability enhancer is present in the formulation (Waters et al.  2013), then useful 
permeability data can be attained.  
 When analysing the permeation of compounds using skin (or skin mimics, such as 
PDMS) there exists a vast collection of donor phase compositions – ranging from water-
based solutions of the model compound (Majumdar et al.  2007) to compositions that 
duplicate the complex formulations intended for market (Watkinson et al.  2010). For 
instance, even in the case of ibuprofen as a model compound, previous work has focused on 
a basic aqueous solvent at a pre-determined pH through to the use of far more complex 
formulations, such as ibuprofen gel, as would be applied on to human skin (Herkenne et al.  
2007) or the addition of surfactants (Waters et al.  2013). However, the question – how, or 
why, certain solvents have been chosen for the donor solution in the majority of cases – has 
been paid very little attention although a recent study within our group has begun to consider 
the role of the binary mixtures present in the donor solution (Shahzad et al.  2014). Such 
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study clearly indicates that donor phase composition can, and does, play a role in compound 
permeation yet the extent to which it occurs has yet to be known.  
 For any aqueous based formulation, the physicochemical behaviour of the compound 
under investigation can be fundamentally dictated by the pH of the chosen solution. By 
knowing the pKa of a compound the percentage ionised can be calculated using the 
Henderson-Hasselbalch equation (Eq. 3.1) at any given pH with the ionised species (A-) 
being in equilibrium with the unionised species (HA).  
                                           pH = p𝐾a + log (
[A−]
[HA]
)                (3.1) 
 Hence, the pH of a solution can be manipulated so that the ratio of the concentration of 
unionised species to that of ionised species can be controlled and determined for any 
compound with a known pKa. Compound permeation can also be influenced by other 
physicochemical factors, such as log P (the octanol-water partition coefficient). Therefore, 
this study selected a set of compounds with a wide range of lipophilicities to confirm the 
importance of this additional determinant on permeation.  
 For the prediction of the behaviour of a compound in a formulation using Franz-cell 
based experiments, researchers often choose donor solutions with pH values analogous to 
those found in vivo. For example, some research has considered a donor solution at low pH 
to mimic the typical skin pH (Guo et al.  2014) whereas others have chosen pH values such 
as 7.4 (Mertz & Sloan 2014). Although such studies focused on the importance of controlling 
and selecting the pH of the donor phase, little attention has been paid to understand the 
relationship between the extent of ionisation and permeation in Franz cell based studies. One 
particular study analysed only one compound, namely salicylic acid, to understand the effect 
of ionisation on the subsequent permeation across human skin and silicone membrane (Smith 
& Irwin 2000). The study found a direct relationship between permeation and the degree of 
ionisation of compound. However, only one specific compound was considered in the study. 
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This study aimed to understand whether a similar relationship would be observed for a range 
of compounds that, upon ionisation, form cationic and anionic species, and have a wide range 
of lipophilicities.   
                                     
3.2 Results and discussion 
3.2.1 Effect of ionisation on compound permeation across PDMS membrane 
Six model compounds were selected to assess the permeation dependence with 
ionisation. The amounts of the compounds permeated through PDMS membrane were 
determined using a flow-through diffusion cell with each compound at three specific 
percentages of ionisation (calculated using Eq. 3.1 and pKa values of 1-methyl-3-
phenylpropylamine 9.79 (U.S National Library of Medicine 2016), benzoic acid 4.2 (Wang 
et al.  2013), benzotriazole 8.2 (Benitez et al.  2015), ibuprofen 4.9 (Willian & Pritchett 
2014), ketoprofen 4.0 (Bechet 1999) and lidocaine 7.8 (Liu et al.  2003). These compounds 
were selected for their diverse range of pKa values and lipophilicities, the latter ranging from 
a log P of 1.2 for benzotriazole (Hart et al.  2004) to 3.6 for ibuprofen (Waters et al.  2010).          
  A previous study (Smith & Irwin 2000) investigated the permeation of salicylic acid 
across PDMS membrane to determine if it followed the pH-hypothesis whereby steady-state 
flux and permeability coefficients increased with a decrease in pH and a linear relationship 
was found between the flux and fraction unionised. The results suggested that the change in 
salicylic acid flux was a direct consequence of pH, which regulated the concentration of 
unionised species. However, the study only considered salicylic acid i.e. one specific 
compound. The aim of this study was to determine if a similar relationship would be observed 
for a diverse range of compounds with different pKa and log P values, i.e. to identify if the 
flux-pH relationship can be applied more generally. The permeation profiles of all six 
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compounds are displayed in Figs. 3.1-3.6 with the cumulative amount permeated shown for 
a period of seven hours.      
    
  
 
 
 
 
 
 
 
 
 
Fig. 3.1: Cumulative amount of 1-methyl-3-phenylpropylamine permeated with percentage 
unionised. Each data point represents the mean ± SD (n = 3). The corresponding pH values 
to obtain 1.6 %, 0.41 % and 0.02 % of unionised compound were 8.0, 7.4 and 6.0, 
respectively.   
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Fig. 3.2: Cumulative amount of benzoic acid permeated with percentage unionised. Each 
data point represents the mean ± SD (n = 3). The corresponding pH values to obtain 33.39 
%, 0.50 % and 0.06 % of unionised compound were 4.5, 6.5 and 7.4, respectively.  
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Cumulative amount of benzotriazole permeated with percentage unionised. Each 
data point represents the mean ± SD (n = 3). The corresponding pH values to obtain 99.37 
%, 98.04 % and 86.32 % of unionised compound were 6.0, 6.5 and 7.4, respectively. 
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Fig. 3.4: Cumulative amount of ibuprofen permeated with percentage unionised. Each data 
point represents the mean ± SD (n = 3). The corresponding pH values to obtain 0.79 %, 0.32 
% and 0.08 % of unionised compound were 7.0, 7.4 and 8.0, respectively. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5: Cumulative amount of ketoprofen permeated with percentage unionised. Each data 
point represents the mean ± SD (n = 3). The corresponding pH values to obtain 0.10 %, 0.04 
% and 0.003 % of unionised compound were 7.0, 7.4 and 8.5, respectively. 
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Fig. 3.6: Cumulative amount of lidocaine permeated with percentage unionised. Each data 
point represents the mean ± SD (n = 3). The corresponding pH values to obtain 1.24 %, 24.02 
% and 61.24 % of unionised compound were 6.0, 7.4 and 8.0, respectively. 
 
Although it was not possible for all six compounds to achieve the same degrees of 
ionisation with their individual pKa values and the pH range available, the distribution of 
percentages allowed a comparative study to be undertaken. It is to be noted that a specific set 
of pH values were chosen to achieve the complete dissolution of the compounds in the buffer 
solutions.  It can be seen that in all cases (Figs. 3.1-3.6) there was a reduction in compound 
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based on the hydrophobic characteristic of PDMS membrane. Through modifying the pH of 
the donor solution (for example from pH 8.5 for ketoprofen through to pH 4.5 for benzoic 
acid) it was interesting to observe a significant change in the degree of compound permeation 
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permeated. A clearer picture of this phenomenon can be drawn by plotting Q7 (the amount 
permeated after 7 h) values against the percentage of compound unionised (Figs. 3.7-3.12). 
A plot of such data allows comparison to be made between the gradients i.e. how influential 
the percentage ionised is on compound permeation across PDMS membrane.   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7: Amount of 1-methyl-3-phenylpropylamine permeated after 7 h at three specific 
percentages of ionisation 
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Fig. 3.8: Amount of benzoic acid permeated after 7 h at three specific percentages of 
ionisation 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9: Amount of benzotriazole permeated after 7 h at three specific percentages of 
ionisation 
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Fig. 3.10: Amount of ibuprofen permeated after 7 h at three specific percentages of ionisation 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11: Amount of ketoprofen permeated after 7 h at three specific percentages of 
ionisation 
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Fig. 3.12: Amount of lidocaine permeated after 7 h at three specific percentages of ionisation 
 
A closer look at the gradient (m) values in Figs. 3.7-3.12 reveals that the most 
dramatic change in amount permeated as a function of percentage unionised was observed 
for ibuprofen and the least change was seen for benzotriazole, possibly as a consequence of 
the pKa with a value of 8.2 for benzotriazole (Benitez et al.  2015). Alternatively, this might 
have been a consequence of the comparative log P values with ibuprofen showing the greatest 
change (m = 670.79) in amount permeated and being the most hydrophobic of the 
compounds, and benzotriazole displaying the least change (m = 1.62) and being the least 
hydrophobic. The R2 values in Figs. 3.7-3.12 show that the overall relationship between the 
amount permeated and the percentage unionised is linear, though benzoic acid (R2 = 0.7797) 
did not show such a clearly linear relationship.  
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upon factors, such as log P. This analysis was performed in a similar manner to that of Smith 
and Irwin (Smith & Irwin 2000) whereby they found a linear relationship for the one 
compound studied, namely salicylic acid. Data for all six compounds are shown in Table 3.1.  
Table 3.1: Permeation data for six model compounds across silicone membrane over a series 
of percentages/fractions unionised 
 
Compound % Unionised 
Fraction 
Unionised 
Steady-state flux 
(µg/cm2/h) 
1-methyl-3-
phenylpropylamine 
 
0.02 2 × 10-4 30.61 ± 0.96 
0.41 4 × 10-3 55.21 ± 2.56 
1.60 0.02 118.09 ± 4.96 
Benzoic acid  
0.06 6 × 10-4 3.80 ± 0.95 
0.50 5 × 10-3 31.91 ± 0.53 
33.39 0.33 75.36 ± 1.21 
Benzotriazole 
86.32 0.86 8.23 ± 0.03 
98.04 0.98 10.68 ± 0.65 
99.37 0.99 11.38 ± 0.23 
Ibuprofen 
0.08 8 × 10-4 23.22 ± 0.10 
0.32 3 × 10-3 32.91 ± 0.82 
0.79 8 × 10-3 89.03 ± 2.30 
Ketoprofen 
0.003 3 × 10-5 1.05 ± 0.10 
0.04 4 × 10-4 1.82 ± 0.11 
0.10 1 × 10-3 2.84 ± 0.07 
Lidocaine 
1.24 0.01 33.99 ± 2.05 
24.02 0.24 91.09 ± 3.14 
61.24 0.61 123.30 ± 1.89 
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Moreover, the flux values were statistically analysed using One-way ANOVA, and 
the calculated p-values for each compound are displayed in Table 3.2.    
 
Table 3.2: p-values calculated using ANOVA test for each compound 
Drug p-values 
1-methyl-3-phenylpropylamine 0.000 
Benzoic acid 0.000 
Benzotriazole 0.000 
Ibuprofen 0.000 
Ketoprofen 0.000 
Lidocaine 0.000 
 
 
 The p-values (Table 3.2) demonstrate that for all compounds a change in fraction 
unionised resulted in a significant change (p < 0.05) in their flux across PDMS membrane. 
Considering the data in Table 3.1, a trend similar to Smith and Irwin 2000 was observed for 
that discussed above, i.e. from comparative consideration of the amount permeated with 
percentage unionised, as all experiments of the study were conducted for seven hours. Again, 
the relationship between fraction unionised and flux was predominantly linear with the one 
exception of benzoic acid where the intermediate fraction of unionised solution seemed to 
show greater flux than expected. This anomaly was unexpected although the general trend 
was similar to that of the remaining compounds. One factor that can certainly be excluded 
from consideration is membrane thickness as this was consistent throughout the study, the 
importance of the consistency of membrane thickness has been mentioned by others (Firpo 
et al.  2015). Overall it can be concluded that steady-state flux increases as the percentage of 
unionised compound increases.           
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3.2.2 iGC SEA membrane surface analysis 
  The BET Specific Surface Area (BET-SSA) of PDMS membrane was determined 
with the adsorption of ethanol molecules by DVS (Dynamic Vapour Sorption) method. To 
calculate the BET specific surface area, the BET equation was employed (Eq. 3.1). 
1
𝑛 [(
𝑝0
𝑝 ) − 1]
=  
𝑐 − 1
𝑛𝑚𝑐
(
𝑝
𝑝0
) + 
1
𝑛𝑚𝑐
… … … … … … … . . (3.1) 
where, 𝑝 and 𝑝0 are the equilibrium and saturation pressure of adsorbates at the temperature 
of adsorption, 𝑛 is the adsorbed gas amount, 𝑛𝑚 is the monolayer adsorbed gas amount, 𝑐 is 
sorption constant. This equation is an adsorption isotherm and a straight line was taken by 
plotting  𝑝/𝑝0 versus 
1
𝑛[(
𝑝0
𝑝
)−1]
 (data not shown). The sorption constant (c) and the monolayer 
capacity (𝑛𝑚) were calculated from the slope and intercept of the line. The surface area was 
determined by the following equation: 
𝑆𝐵𝐸𝑇 =  
(𝑛𝑚𝑁𝐴𝑣𝑎)
𝑉𝑚
… … … … … … … … … (3.2) 
where, 𝑛𝑚 is the monolayer adsorbed gas amount, 𝑁𝐴𝑣 is the Avogadro’s number, 𝑎 is the 
adsorption cross section of the adsorbing species, 𝑉 is the molar volume of adsorbed gas and 
𝑚 is the mass of adsorbent (in g). 
The results are presented in Table 3.3.  
Table 3.3: Specific surface area data for PDMS membrane using iGC 
 
The dispersive (sd), acid-base (sab) and total surface energy (st) profiles of the membrane 
are shown in Fig. 3.13. The profiles show that the sample is energetically heterogeneous, i.e. 
Sorption constant 
Monolayer capacity 
(cm3/g) 
BET Specific Surface 
Area (m2/g)  
R2 
5.832 2.061 19.560 0.999 
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the surface energy changed as a function of surface coverage with a major contribution from 
the dispersive component. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.13: Surface energy profiles (as a function of surface coverage) of PDMS membrane 
 
 
 To represent the heterogeneity of the sample in a more illustrative manner, the surface 
energy distributions were obtained by a point-by-point integration of the surface energy 
profiles, resulting in plots of sd, sab and st surface energy versus percentage of surface (area 
increment), as shown in Fig. 3.14. As expected, the energetically heterogeneous membrane 
has a wide variation of surface active sites. Fig. 3.14 shows that the membrane exhibits a 
relatively wide range of  sd distribution, ranging from 10.12 to 30.19 mJ/m2 and with a mean 
value of 13.88 mJ/m2.   
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Fig. 3.14: Dispersive surface energy distribution for PDMS membrane 
 
 
 Furthermore, the specific (acid-base) Gibbs free energy of adsorption (∆Gsp) changed 
with surface coverage, again confirming the heterogeneous nature of the membrane. The 
∆Gsp profiles, resulted from the interactions of the membrane with five polar probe 
molecules, are shown in Fig. 3.15. From analysing the interactions with the polar probe 
molecules the rank order of decreasing ∆Gsp was found to be acetonitrile > ethanol > 
dichloromethane > acetone > ethyl acetate although the membrane showed only a relatively 
small degree of interactions with all five probes.  
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Fig. 3.15: Specific (acid-base) free energy of different solvents for PDMS membrane 
 
 The surface chemistry of the membrane was assessed by Gutmann acid (Ka) and base 
(Kb) numbers, determined using the following probes: dichloromethane, ethyl acetate, 
acetonitrile and chloroform. Ka and Kb values of the membrane were calculated using the 
∆Gsp values of the polar probes at the particular surface coverage (Fig. 3.16). It can be seen 
that Kb values are consistently higher than Ka. These results indicate that the surface of PDMS 
membrane is basic in nature and possesses a high concentration of electron-donating surface 
functional groups. These can be the Lewis bases in the form of bridging oxygen atoms in Si-
O-Si backbone. Moreover, there may be some residual un-substituted hydroxyl groups from 
the manufacturing process (based on the chemistry of the material).    
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Fig. 3.16: Gutmann acid and base number profiles of PDMS membrane 
 
  The above-mentioned findings can be linked with the previously discussed 
permeation data to elucidate why it was always the more unionised form of a compound that 
favoured permeation. This can be explained in terms of the iGC data which indicated the 
basicity of the PDMS surface. Thus it can be expected that the basic surface would repel the 
ionised form of the acid compounds (benzoic acid, benzotriazole, ibuprofen and ketoprofen) 
and weakly bond the ionised form of basic compounds (1-methyl-3-phenylpropylamine and 
lidocaine). In either case, the ionised form of a compound would be less inclined to permeate 
through the basic membrane surface than the unionised form.      
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3.3 Conclusion 
The results confirm that permeation has a dependence on compound ionisation. 
Permeation experiments of six compounds were carried out using PDMS membrane, with 
each compound at three specific percentages of ionisation. The surface energetics and surface 
chemistry of the membrane were determined using iGC SEA. The iGC data showed that the 
membrane is energetically heterogeneous and more basic in nature.  
From considering the combined results of the permeation study and iGC SEA it can 
be seen that data presented based on permeation suggests there is a general preference for 
permeation for the most unionised forms for all compounds. Based on these findings it can 
be concluded that the overall hydrophobic nature of PDMS membrane outweighs the effects 
of any surface groups that might be present. Alternatively, there might be the existence of a 
peripheral layer of basic groups that creates an electrostatic attraction or repulsion for the 
ionised species of compounds, thus hindering their permeation. In either case, the permeation 
would be more favourable for the more unionised form of a compound notwithstanding the 
presence of a basic membrane surface.     
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Chapter 4: Effect of surfactant type on the permeation of 
pharmaceutical compounds through silicone membrane 
  
This chapter examines the effects of different surfactants on drug permeation across 
polydimethylsiloxane (PDMS) membrane. Four model compounds were investigated to 
determine their permeation through PDMS in the presence of four types of surfactants, 
namely, anionic, cationic, non-ionic and zwitterionic surfactants.          
 
4.1 Introduction 
Pharmaceutical formulations often include excipients that are known to have human 
skin penetration effects (HSPE). Some examples of these excipients are terpenes (Kang et al.  
2007), pluronic gels (Escobar-Chávez et al.  2005), fatty acid esters (Casiraghi et al.  2012), 
nanoemulsions (Barakat et al.  2011) and liposomes (Bouwstra & Honeywell-Nguyen 2002). 
Another class of compounds that are known to alter skin permeation is surfactants (Walters 
et al.  1993; Shokri et al.  2001) where they intercalate with the continuous lipid region of 
stratum corneum, thus facilitating fluidity. A number of studies has reported their use to 
enhance transdermal permeation of compounds. One of the studies was carried out by Borras-
Blasco et al. (1997) which estimated the influence of an anionic surfactant, namely sodium 
lauryl sulphate (SLS), on the penetration of seven model compounds of a wide range of 
lipophilicities across rat skin, and they found SLS to be a penetration enhancer depending on 
the lipophilicities of the compounds. Some other studies were carried out to examine the 
penetration effect of cationic surfactant such as CTAB (cetyltrimethylammonium bromide) 
and non-ionic surfactant such as Tween 80. For example, Nokhodchi et al. (2003) 
investigated the effect of CTAB and Tween 80 on Lorazepam permeation across rat skin and 
observed a significant enhancement caused by both of the surfactants. Zwitterionic 
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surfactants such as CHAPS have been reported to enhance mannitol permeability across 
Caco-2 cells, an in vitro model for mimicking intestinal mucosa (Nerurker et al.  1996). 
Nevertheless in some circumstances surfactants were observed to initiate only a minimal 
enhancement. One such study approached an attempted enhancement of methotrexate 
permeation using a variety of surfactants, where SLS did not produce a substantial 
enhancement effect (Javadzadeh & Hamishehkar 2011). To summarise, the presence of 
surfactants, along with other factors, are known to alter compound permeation across 
biological membranes, though little research has investigated the impact of such changes 
with respect to silicone membrane – a widely accepted artificial in vitro skin mimic. One 
particular study has investigated the effect of two surfactants, namely sodium dodecyl sulfate 
and Brij 35, on the permeation of methylparaben and ethylparaben through silicone 
membrane (Waters et al.  2013).  The paraben derivatives, considered in the study, are widely 
used excipients in cosmetic and pharmaceutical products. However, the study found a 
reduction in paraben permeation in the presence of SDS (an anionic surfactant) whereas Brij 
35 (a non-ionic surfactant) did not show any significant effect. Whether a similar relationship 
would be observed for a range of surfactants such as cationic or zwitterionic types, or a range 
of therapeutic compounds was not considered. Hence, this study investigates the permeation 
of a range of therapeutic compounds through silicone membrane in the presence of four types 
of surfactants.                      
 
4.2 Results and discussion 
A set of four model compounds were examined to assess the permeation effect of 
different surfactants across silicone (PDMS) membrane. The model compounds were 
benzocaine, benzotriazole, ibuprofen and lidocaine. These compounds were selected because 
of their diverse range of lipophilicities ranging from a log P of 1.2 for benzotriazole (Hart et 
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al.  2004) to 3.6 for ibuprofen (Waters & Bhuiyan 2016). The surfactants selected for this 
study were SDS (an anionic surfactant), CTAB (a cationic surfactant), CHAPS (a zwitterionic 
surfactant), Brij 35 and Tween 80 (non-ionic surfactants) i.e. to encompass all four types. 
As a control, the permeation of the model compounds through silicone membrane 
were assessed at 32 °C with no surfactant present in the donor solution over a period of 6 
hours. Three additional solutions were then prepared containing the surfactants at three 
different concentrations (4, 8 and 20 mM for SDS, CTAB, Brij 35 and Tween 80, and 2, 4 
and 20 mM for CHAPS) and the permeation of the model compounds were measured. In all 
cases, the donor solution pH was 7.4. The concentrations of the surfactants were chosen to 
be, where suitable , either below, equal or above the critical micellar concentration (CMC). 
The CMCs of the surfactants considered for this study were 8 mM for SDS (Waters et al.  
2013), 0.83 mM for CTAB (Prazeres et al.  2012), 0.09 mM for Brij 35, 0.012 mM for Tween 
80 (Chou et al.  2005) and 4-6 mM for CHAPS (Chattopadhyay & Harikumar 1996). Two 
permeation parameters i.e. steady-state flux (𝐽) and the cumulative amount of compound 
permeated after 6 hours (Q6) were calculated from the data obtained using a flow-through 
diffusion cell system and are summarised in Table 4.1, 4.2, 4.5 and 4.6. The steady-state flux 
(𝐽) values of the compounds were analysed statistically using One-way ANOVA, and the 
calculated p-values for each compound and surfactant are presented in Table 4.3 and 4.4. The 
p-values in Table 4.3 reflect whether there is a difference in compound permeation owing to 
a change in surfactant concentration, and that in Table 4.4 shows whether the variability in 
surfactant types caused a significant difference in compound permeability.  
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Table 4.1: Steady-state flux values of four model compounds in the presence of SDS, CTAB, 
Brij 35 and Tween 80 across silicone membrane 
* To examine the permeation effect of Tween 80, only three model compounds, namely, benzocaine, 
ibuprofen and lidocaine, were studied. Benzotriazole was not studied in this instance. This is because 
the purpose of using Tween 80 was only to confirm the phenomenon associated with Brij 35 
(discussed later in this chapter).      
 
C
o
m
p
o
u
n
d
 
S
u
rf
ac
ta
n
t Steady-state flux (µg/cm
2/h) of compound at three different surfactant 
concentrations 
0 mM (control) 4 mM 8 mM 20 mM 
B
en
zo
ca
in
e 
SDS 97.92 ± 2.22 89.80 ± 1.70 89.16 ± 0.85 62.87 ± 1.84 
CTAB 104.59 ± 3.22 70.77 ± 6.79 56.71 ± 2.94 38.82 ± 5.48 
Brij 35 102.07 ± 6.88 77.54 ± 5.67 63.29 ± 2.61 43.36 ± 1.15 
Tween 
80 
106.66 ± 3.15 78.50 ± 0.55 65.33 ± 1.72 43.34 ± 0.40 
B
en
zo
tr
ia
zo
le
 *
 
SDS 18.33 ± 0.80 17.94 ± 0.43 13.75 ± 0.23 12.21 ± 0.26 
CTAB 9.96 ± 0.58 9.51 ± 0.27 8.00 ± 0.25 6.88 ± 0.23 
Brij 35 13.30 ± 0.09 13.04 ± 0.73 10.62 ± 0.43 9.58 ± 0.37 
Ib
u
p
ro
fe
n
 
SDS 26.25 ± 1.95 27.53 ± 1.40 23.37 ± 1.27 21.29 ± 1.55 
CTAB 21.15 ± 1.46 9.82 ± 0.55 5.12 ± 0.75 2.37 ± 0.31 
Brij 35 31.00 ± 1.83 26.50 ± 1.69 17.49 ± 0.12 12.29 ± 0.33 
Tween 
80 
28.20 ± 1.48 21.53 ± 1.25 14.76 ± 0.55 9.96 ± 0.17 
L
id
o
ca
in
e 
SDS 69.70 ± 1.12 43.07 ± 1.70 31.69 ± 3.10 13.54 ± 1.08 
CTAB 56.98 ± 6.64 52.93 ± 4.63 47.77 ± 6.77 37.66 ± 3.23 
Brij 35 64.84 ± 3.66 66.96 ± 3.09 60.48 ± 4.07 57.44 ± 2.57 
Tween 
80 
60.05 ± 0.92 65.14 ± 8.52 61.23 ± 5.74 44.45 ± 1.00 
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Table 4.2: Steady-state flux values of the model compounds in the presence of CHAPS 
across silicone membrane  
 
In an ideal condition, all donor solutions of the same penetrant should yield an 
identical steady-state flux across a membrane, not depending on the composition of the 
vehicle, provided that the formulation components do not interact with the membrane (Dias 
et al.  2007). Therefore, the steady-state flux of a compound from donor solutions from any 
of the surfactant-containing vehicles would be anticipated to be same. However, the data 
presented in Table 4.1 and 4.2 demonstrate that the flux values of the penetrants are not 
identical. This indicates that the situations were not ideal and, approximately in all cases, 
interactions between either surfactant and membrane, or drug and surfactant were observed 
that could possibly alter the compound flux across the membrane. These types of interactions 
can be affected by the choice of surfactant concentration and surfactant types. The p-values 
in Table 4.3 show the evidence of a significant difference in permeation owing to a change 
in surfactant concentration whereas Table 4.4 indicates that compound permeation can also 
be affected by different surfactant types. 
 
 
 
 
C
o
m
p
o
u
n
d
 
S
u
rf
ac
ta
n
t Steady-state flux (µg/cm
2/h) of compound at three different 
concentrations of CHAPS 
0 mM 
(control) 
2 mM 4 mM 20 mM 
Benzocaine CHAPS 107.95 ± 3.99 105.10 ± 6.75 106.75 ± 5.42 87.53 ± 4.10 
Benzotriazole CHAPS 10.46 ± 0.53 10.14 ± 0.51 9.45 ± 0.26 9.47 ± 0.18 
Ibuprofen CHAPS 32.13 ± 1.12 32.48 ± 1.76 18.50 ± 0.39 9.90 ± 1.93 
Lidocaine CHAPS 55.28 ± 6.64 54.68 ± 3.73 52.62 ± 3.05 49.94 ± 4.01 
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Table 4.3: p-values calculated using ANOVA test for each compound and surfactant 
Compound Surfactant  p-values 
Benzocaine SDS 0.000 
CTAB 0.000 
Brij 35 0.000 
CHAPS 0.004 
Tween 80 0.000 
Benzotriazole SDS 0.000 
CTAB 0.000 
Brij 35 0.000 
CHAPS 0.035 
Ibuprofen SDS 0.005 
CTAB 0.000 
Brij 35 0.000 
CHAPS 0.000 
Tween 80 0.000 
Lidocaine SDS 0.000 
CTAB 0.012 
Brij 35 0.034 
CHAPS 0.510 
Tween 80 0.006 
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Table 4.4: p-values calculated using ANOVA test for each compound and surfactant (20 
mM) 
 SDS  CTAB  CHAPS  Brij 35  Tween 80  
SDS    
B: 0.002 
BT: 0.000 
I: 0.000 
L: 0.000 
B: 0.001 
BT: 0.000 
I: 0.001 
L: 0.000 
B: 0.000 
BT: 0.001 
I: 0.001 
L: 0.000 
B: 0.000 
I: 0.000 
L: 0.000 
CTAB  
B: 0.002 
BT: 0.000 
I: 0.000 
L: 0.000 
 
B: 0.000 
BT: 0.000 
I: 0.003 
L: 0.015 
B: 0.233 
BT: 0.000 
I: 0.000 
L: 0.001 
B: 0.228 
I: 0.000 
L: 0.025 
CHAPS  
B: 0.001 
BT: 0.000 
I: 0.001 
L: 0.000 
B: 0.000 
BT: 0.000  
I: 0.003 
L: 0.015 
  
B: 0.000 
BT: 0.686 
I: 0.102 
L: 0.053 
B: 0.000 
I: 0.962 
L: 0.083 
Brij 35  
B: 0.000 
BT: 0.001 
I: 0.001 
L: 0.000 
B: 0.233 
BT: 0.000 
I: 0.000 
L: 0.001 
B: 0.000 
BT: 0.686 
I: 0.102 
L: 0.053 
  
B: 0.972 
I: 0.000 
L: 0.001 
Tween 80  
B: 0.000 
I: 0.000 
L: 0.000 
B: 0.228 
I: 0.000 
L: 0.025 
B: 0.000 
I: 0.962 
L: 0.083 
B: 0.972 
I: 0.000 
L: 0.001 
  
B, Benzocaine; BT, Benzotriazole; I, Ibuprofen; L, Lidocaine. 
 
  
To understand the effect of individual surfactant type and concentration, the 
cumulative amount of compound permeated after 6 h were tabulated in Table 4.5 and 4.6. It 
can be seen from these tables that the amount of the model compounds permeated after 6 
hours varies with a change in surfactant concentration and type. Moreover, permeability 
profiles were shown as percentage permeated after 6 h, graphically, in Figs. 4.1 – 4.4 in an 
attempt to provide a comprehensive understanding of the relationship between the surfactant 
concentration and the reduction in the amount permeated. In all of the figures (Figs. 4.1 – 
4.4) the amount permeated after 6 h for the control solution was considered 100 %, and then 
the calculations for other solutions were performed accordingly. The data from all 
calculations are shown in Tables 4.7 and 4.8. Such presentations offer a convenient way of 
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comparing different active compounds in terms of the effect on their permeation by a 
surfactant.      
 
Table 4.5: The values of cumulative amount permeated after 6 hours (Q6) of four model 
compounds in the presence of various surfactants across PDMS membrane  
 
 
C
o
m
p
o
u
n
d
 
S
u
rf
ac
ta
n
t Q6 values (µg/cm
2) of compound at three different surfactant 
concentrations 
0 mM 
(control) 
4 mM 8 mM 20 mM 
B
en
zo
ca
in
e 
SDS 570.65 ± 13.00 526.98 ± 11.19 520.29 ± 4.56 
370.01 ± 
10.93 
CTAB 611.95 ± 20.24 412.35 ± 37.75 336.94 ± 17.46 
229.99 ± 
31.91 
Brij 35 600.99 ± 39.63 456.40 ± 32.33 372.96 ± 14.80 257.46 ± 6.52 
Tween 
80 
 627.31 ± 19.04  461.77 ± 3.21  386.27 ± 10.18  257.13 ± 2.28 
B
en
zo
tr
ia
zo
le
 
SDS 110.80 ± 3.90 108.55 ± 2.60 83.72 ± 1.33 74.63 ± 1.24 
CTAB 60.06 ± 3.23 57.66 ± 2.03 48.92 ± 1.40 41.99 ± 1.41 
Brij 35 80.90 ± 0.64 79.45 ± 4.24 64.79 ± 2.29 58.10 ± 2.22 
Ib
u
p
ro
fe
n
 
SDS 155.67 ± 10.95 163.60 ± 8.24 138.18 ± 6.53 126.20 ± 9.45 
CTAB 126.09 ± 8.67 60.67 ± 3.51 31.88 ± 4.27 15.23 ± 1.80 
Brij 35 185.47 ± 10.62 158.84 ± 10.30 105.09 ± 0.51 74.88 ± 2.15 
Tween 
80 
  167.61 ± 8.62 127.94 ± 7.75  87.54 ± 3.07  59.84 ± 1.10 
L
id
o
ca
in
e 
SDS 410.35 ± 8.29 253.74 ± 11.36 187.76 ± 17.99 81.17 ± 6.68 
CTAB 333.97 ± 37.25 314.68 ± 27.91 283.63 ± 41.67 
221.73 ± 
20.32 
Brij 35 380.52 ± 22.63 394.04 ± 18.87 354.49 ± 24.16 
337.36 ± 
15.73 
Tween 
80 
352.27 ± 5.62  383.75 ± 51.90  359.09 ± 34.18  258.94 ± 5.46 
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Table 4.6: The values of cumulative amount permeated after 6 hours (Q6) of four model 
compounds in the presence of CHAPS across PDMS membrane  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
m
p
o
u
n
d
 
S
u
rf
ac
ta
n
t Q6 values (µg/cm
2) of compound at three different 
concentrations of CHAPS 
0 mM 
(control) 
2 mM 4 mM 20 mM 
Benzocaine CHAPS 635.17 ± 23.38 617.92 ± 41.17 630.04 ± 31.97 
517.98 ± 
24.85 
Benzotriazole CHAPS 62.59 ± 3.57 61.18 ± 3.07 56.85 ± 1.67 
56.72 ± 
1.16 
Ibuprofen CHAPS 188.30 ± 7.40 194.57 ± 10.60 109.94 ± 1.93 
59.05 ± 
11.19 
Lidocaine CHAPS 322.81 ± 39.99 318.98 ± 21.29 308.78 ± 19.19 
293.14 ± 
24.37 
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Table 4.7: The values of percentage (%) permeated after 6 h of four model compounds in 
the presence of various surfactants across PDMS membrane  
 
 
 
 
 
 
C
o
m
p
o
u
n
d
 
S
u
rf
ac
ta
n
t % permeated of compound after 6 h at three different surfactant 
concentrations 
0 mM 
(control) 
4 mM 8 mM 20 mM 
B
en
zo
ca
in
e
 
SDS 100 ± 2.28 92.35 ± 1.96 91.17 ± 0.80 64.84 ± 1.92 
CTAB 100 ± 3.31 67.38 ± 6.17 55.06 ± 2.85 37.58 ± 5.21 
Brij 35 100 ± 6.59 75.94 ± 5.38  62.06 ± 2.46 42.84 ± 1.08 
Tween 
80 
     100 ± 3.04     73.61 ± 0.51    61.58 ± 1.62  40.99 ± 0.36 
B
en
zo
tr
ia
zo
le
 
SDS 100 ± 3.52 97.97 ± 2.35 75.56 ± 1.20 67.36 ± 1.12 
CTAB 100 ± 5.38 96.00 ± 3.38 81.45 ± 2.33 69.91 ± 2.35 
Brij 35 100 ± 0.79  98.21 ± 5.24  80.09 ± 2.83 71.82 ± 2.74 
Ib
u
p
ro
fe
n
 
SDS 100 ± 7.03 105.09 ± 5.29 88.76 ± 4.19 81.07 ± 6.07 
CTAB 100 ± 6.88 48.12 ± 2.78 25.28 ± 3.39 12.08 ± 1.43 
Brij 35 100 ± 5.73 85.64 ± 5.55 56.66 ± 0.27 40.37 ± 1.16 
Tween 
80 
     100 ± 5.14    76.33 ± 4.62    52.23 ± 1.83 35.70 ± 0.66 
L
id
o
ca
in
e 
SDS 100 ± 2.02 61.84 ± 2.77 45.76 ± 4.38 19.78 ± 1.63 
CTAB 100 ± 11.15  94.22 ± 8.36 84.93 ± 12.48 66.39 ± 6.08 
Brij 35 100 ± 5.95 103.55 ± 4.96 93.16 ± 6.35 88.66 ± 4.13 
Tween 
80 
     100 ± 1.60 108.94 ± 14.73 101.94 ± 9.70 73.22 ± 1.55 
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Table 4.8: The values of % permeated after 6 hours of four model compound in the presence 
of CHAPS across PDMS membrane  
 
In the first set of experiments, permeation of benzocaine, benzotriazole, ibuprofen 
and lidocaine through silicone membrane from the donor solutions containing SDS (an 
anionic surfactant) at three different concentrations (4, 8 & 20 mM) were evaluated. It can 
be seen in Fig. 4.1, and also in Table 4.3, that the presence of the anionic surfactant 
significantly (p < 0.05) affected the transport of all compounds over a period of 6 h with the 
lowest percentage permeated observed at the highest concentration of surfactant examined.  
Overall, the results here would indicate that the reduction in the amount permeated is 
directly related to the concentration of surfactant. These results are similar to the findings of 
a recent study where Waters and co-researchers reported a decrease in the permeation of 
paraben derivatives with an increase in SDS concentration in the donor solution (Waters et 
al.  2013).  It can be seen in Fig. 4.1 that the maximum reduction in permeation of each 
compound resulted from 20 mM SDS being present in the donor compartment, with lidocaine 
experiencing a reduction of 80.22 %, being the highest when compared with other model 
compounds, and ibuprofen having a reduction of 18.93 %, being the lowest.  
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0 mM 
(control) 
2 mM 4 mM 20 mM 
Benzocaine CHAPS 100 ± 3.68 97.28 ± 6.48 99.19 ± 5.03 
81.55 ± 
3.91 
Benzotriazole CHAPS 100 ± 5.70 97.75 ± 4.90 90.83 ± 2.67 
90.62 ± 
1.85 
Ibuprofen CHAPS 100 ± 3.93 103.33 ± 5.63 58.39 ± 1.02 
31.36 ± 
5.94  
Lidocaine CHAPS 100 ± 12.39  98.81 ± 6.60 95.65 ± 5.94 
90.81 ± 
7.55 
 
87 
 
 
 
 
 
 
 
 
Fig. 4.1: Effect of the presence of SDS on compound permeation across PDMS membrane 
  
The other noticeable phenomenon in Fig. 4.1 is that the permeability profiles of 
benzocaine, benzotriazole, and ibuprofen, position themselves, more likely, to be part of a 
group whereas lidocaine is very distinctive in this regard. Therefore, the scenario suggests 
that SDS is behaving differently to two groups which can be based on their physicochemical 
properties. From the physicochemical perspective, lidocaine is basic in nature whereas the 
other three compounds are acidic. Thus, upon ionisation in buffer solution, lidocaine 
produces cations while benzocaine, benzotriazole, and ibuprofen, produce anions. Hence, the 
compounds, in donor solutions, would exist as ionised (charged) species and unionised 
(neutral) species. As PDMS membrane is predominantly hydrophobic in nature, only the 
neutral species can pass through the membrane while the charged species stay in the donor 
solution. Although both the neutral and charged (anionic and cationic) species can interact 
with SDS, the interaction of SDS with an anion could not be the same to that with a cation, 
and this variation might result in the compounds experiencing a dissimilar effect from SDS.         
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From the above discussion, it is clear that the influence on compound permeability 
can result from a multidimensional interaction or a mixture of interactions, such as, 
surfactant-membrane, and/or surfactant-drug interaction. One study suggested surfactant-
membrane interaction to be a triggering factor in the reduction of compound permeation 
(Waters et al.  2013). Their study assumed that the hydrophobic tail of SDS was submerged 
within PDMS membrane, thus, resulting in the charged head group exposed to the donor 
solution. Therefore, they proposed that the SDS impregnated membrane surface create a 
negatively charged environment which would, in turn, repel the neutral species of compound. 
Their study also, similar to this study, found 20 mM SDS to produce a greater hindrance in 
permeation than all others (0, 4 and 8 mM SDS) which, they suggested, is because of the 
coexistence of free monomer, monomer-membrane surface interactions and micellisation. It 
is noticeable that the above-mentioned mechanisms offer a comprehensive explanation of 
SDS effect on the overall reduction in compound permeation. However, the fact that SDS 
produces a dissimilar effect for different compounds cannot be addressed by applying these 
mechanisms. Therefore, a detailed look at surfactant-drug or surfactant-membrane 
interactions would be necessary.  
As mentioned above, only the unionised form of compound can permeate through 
PDMS membrane. Thus, the extent of permeation depends on the availability of compounds 
in their unionised form in the donor compartment of the diffusion cell. In a solution, an 
equilibrium exists between unionised and ionised forms while maintaining a specific ratio 
between two forms depending on the pH of the solution. For example, in a buffer solution of 
pH 7.4, ibuprofen would have 0.32 % of total as neutral (unionised) and 91.68 % as anionic 
(ionised) species whereas lidocaine would have 24.02 % as neutral and 75.98 % as cationic 
species. This ratio gives the actual percentage of species in the donor solution, provided that 
they do not interact with other components such as surfactant. However, this might not be 
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the case for lidocaine. As lidocaine produces cations in the solution, a portion of these ions 
might weakly bond the anionic head groups of SDS. In other words, a portion of cationic 
lidocaine molecules, from the bulk solution, will migrate to the SDS-submerged membrane 
surface. Therefore, to maintain the equilibrium ratio between two species (ionised and 
unionised) in the bulk solution a certain number of unionised species would be converted to 
the ionised form which, in turn, decrease the number of neutral (unionised) lidocaine 
molecules available to diffuse through the membrane. In the case of a micellar surfactant 
solution, an additional interaction can happen where cationic lidocaine species interact with 
SDS head groups in the micelles thus further decreasing the number of neutral lidocaine 
molecules that would pass through the membrane. In both cases, the permeation of lidocaine 
would be further reduced. These scenarios might not be observed for benzocaine, 
benzotriazole and ibuprofen, as upon ionisation they produce anions which would be repelled 
by the SDS head group, and stay in the bulk solution i.e. the equilibrium ratio of ionised and 
unionised forms would not be affected.  
A second type of surfactant was investigated in this study, namely a cationic 
surfactant, cetyltrimethylammonium bromide (CTAB). Fig. 4.2 shows the permeability 
profiles of the compounds in the presence of CTAB. Fig. 4.2, along with the p-values (< 0.05) 
from Table 4.3, clearly indicate that the compound fluxes were significantly influenced by 
the cationic surfactant being present in the donor solution.    
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Fig. 4.2: Effect of the presence of CTAB on compound permeation across PDMS membrane 
 
Such an effect of CTAB was hypothesised in a study by Waters and co-researchers 
(Waters et al.  2013) where they assumed that CTAB would reduce the transport of paraben 
derivatives (the model compounds considered in their study) across PDMS membrane. Their 
hypothesis stated that CTAB would create a positively charged membrane surface i.e. the 
hydrophobic tail of CTAB would be submerged within PDMS membrane thus exposing the 
cationic head group to the donor solution, and consequently, this would reduce the likelihood 
of the permeation of neutral paraben molecules through the membrane. The same mechanism 
could be observed in this study. In other words, the positively charged CTAB-submerged 
membrane surface could repel the compound molecules away from the membrane resulting 
in an overall reduction in permeation. As mentioned earlier (in the case of SDS), though this 
mechanism may explain the reduction of compound permeation in general, it cannot clarify 
the inter-difference amongst the compounds in terms of percentage reduced. It can be seen 
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from Fig. 4.2 that the percentage of the amount reduced by CTAB is different for each 
compound.  
Although both SDS and CTAB create a barrier effect in compound permeability, the 
overall trend they follow is different. From Fig. 4.1 and 4.2, if the percentages of overall 
reduction are placed in an order, then for CTAB the order appears as ibuprofen > benzocaine 
> lidocaine > benzotriazole whereas, for SDS it becomes lidocaine > benzocaine > 
benzotriazole > ibuprofen. In general, the reduction effect of both these surfactants on 
compound permeation is different for each drug. Previously, it was mentioned that the 
difference produced by SDS was due to the interaction between its anionic head groups and 
ionised compound species in the donor solution. In the case of CTAB, the difference in 
compound reduction can be the result of the interaction between its cationic head groups and 
ionised species of the compounds. To explain, it can be assumed that the hydrophobic regions 
of CTAB are submerged in PDMS membrane thus exposing the cationic head groups to the 
donor solution and making a positively charged membrane surface. A portion of anionic 
species, which are formed upon ionisation of acid compounds, may migrate to the positively 
charged membrane surface, and weakly bond the cationic head groups of CTAB. 
Consequently, to maintain the equilibrium ratio between ionised and unionised forms of acid 
compounds in the bulk solution, a number of unionised species are converted to the ionised 
(anionic) species, thus, decreasing the total available number of neutral molecules to be 
transported across the membrane. In the case of a micellar solution, the number of neutral 
molecules can be further decreased because of the interaction between the anionic form of 
the compound and the cationic head group of CTAB. In both scenarios, the compound would 
experience a reduction in transport through membrane. However, the aforementioned 
circumstances may not be observed for lidocaine as it forms a cation upon ionisation which 
is repelled by the cationic CTAB head. Unexpectedly, though benzotriazole forms an anion 
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upon ionisation, it was not affected by the scenarios mentioned above. This may be the result 
of a complex chemical interaction which is currently unclear and the focus of current study. 
The third type of surfactant, investigated in this study, was a zwitterionic surfactant, 
namely CHAPS. The effect of CHAPS on compound permeation is shown in Fig. 4.3.                            
Fig. 4.3: Effect of the presence of CHAPS on compound permeation across PDMS 
membrane 
It appears that the overall permeation of compounds, except for ibuprofen, was not 
significantly affected by CHAPS. It is also observable that the permeation of ibuprofen was 
reduced only in the presence of CHAPS being present at, and above its CMC which is 4 mM. 
At 2 mM, i.e. below the CMC, CHAPS did not affect ibuprofen permeation. This may be the 
result of an interaction between the ibuprofen molecules and CHAPS micelles as upon 
reaching the CMC, the surfactant forms micelles. The formation of surfactant micelles creates 
a hydrophobic core which contains the hydrophobic regions of surfactant. One study reported 
that the hydrophobic core of micelles can strongly interact with hydrophobic molecules and 
entrap them inside the core (Tehrani-Bagha & Holmberg 2013). A similar mechanism can be 
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observed in this study where ibuprofen, with a log P value of 3.6, strongly interacted with the 
hydrophobic core of CHAPS micelles and became trapped inside them thus reducing the 
number of ibuprofen molecules available to cross through PDMS membrane. Consequently, 
there would be a reduction in ibuprofen permeation. As the other three compounds are 
relatively less hydrophobic, they might not as strongly interact with CHAPS micelles and 
hence, their fluxes would not be significantly affected. 
This study also investigated the effect of a non-ionic surfactant, namely Brij 35, on 
drug transport across PDMS membrane. The results (Fig. 4.4 and Table 4.8) indicate that the 
presence of this non-ionic surfactant significantly retarded the overall transport of all 
compounds except for lidocaine. It can also be seen that the fluxes of lidocaine and 
benzotriazole remain unaffected in the case of 4 mM Brij 35.  
Fig. 4.4: Effect of the presence of Brij 35 on compound permeation across PDMS membrane 
Nevertheless, in general, an increase in the concentration of Brij 35 resulted in a 
decrease in the flux of the compounds. Interestingly, this finding appears to be different than 
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that observed in a recent study (Waters et al. 2013). In that study, Brij 35 was reported not to 
have a significant effect on compound permeation through PDMS membrane. The study 
considered paraben derivatives, namely, methylparaben and ethylparaben as model 
compounds. However, to investigate whether such an anomaly of Brij 35 effect results from 
its particular interaction with different model compounds based on their physicochemical 
properties, some relevant properties of all compounds from both studies, were tabulated and 
compared (Table 4.9). 
Table 4.9: The physicochemical properties1 of the model compounds  
Compound Log P 
Polar surface 
area (Å2) 
Free rotating 
bonds  
H bond 
acceptors 
H bond 
donors 
Methylparaben 1.87 47 2 3 1 
Ethylparaben 2.40 47 3 3 1 
Benzocaine 1.95 52 3 3 2 
Benzotriazole 1.34 42 0 3 1 
Ibuprofen 3.72 37 4 2 1 
Lidocaine 3.63 36 5 3 1 
1The physicochemical properties were generated from ACD/Labs, RSC, UK 
A closer look at Table 4.9 reveals that there is no observable pattern in the 
physicochemical characteristics of the compounds which could explain the anomaly in Brij 
35 effect on their permeation. Hence, further investigation, such as a calorimetric study of 
surfactant-compound interaction, could be useful and remains the focus of current study.  
However, to confirm if this phenomenon is a result of Brij 35 in particular (or a more 
broadly observed trend of non-ionic surfactant) a further study was carried out focusing on 
the permeation of three model compounds (benzocaine, ibuprofen and lidocaine) in the 
presence of another non-ionic surfactant, namely Tween 80.  
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Fig. 4.5: Effect of the presence of Tween 80 on compound permeation across PDMS 
membrane 
Fig. 4.5 clearly shows that the presence of this non-ionic surfactant retards the 
permeation of the compounds in a similar trend to that observed for Brij 35. Therefore, it can 
be inferred that this non-ionic surfactant does affect compound permeation. 
In summary, the current study demonstrates that all five surfactants investigated here 
had a significant effect on compound permeation. Comparing different concentrations of 
various surfactants, it is obvious from Table 4.1 that the solution containing 20 mM surfactant 
leads to the lowest flux of compound across PDMS membrane. However, while the 
surfactants show the greatest reduction effect at 20 mM, clear differences can be found in 
their effect at this concentration (Fig. 4.6). It also appears from Fig. 4.6 that among the four 
surfactants tested, CTAB facilitates the lowest flux in the case of all compounds, except for 
lidocaine – the lowest flux of lidocaine was obtained in the presence of SDS. The same trend 
was observed for the surfactants being present in the donor solution at a concentration of 4 
mM (figure not shown).       
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Fig. 4.6: Effect of the presence of surfactant (20 mM) on compound permeation across 
PDMS membrane 
 While the studies reported here demonstrate a phenomenon common to all 
surfactants, there was a clear difference in their effect on compound permeation through 
silicone membrane. Creating a detailed mechanistic picture of this difference would require 
an in-depth investigation of surfactant- compound -membrane interactions using techniques 
such as calorimetric techniques, and is the focus of a current study. 
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4.3 Conclusion 
The current study exhibits a wider perspective of surfactant effect on compound 
permeation across silicone membrane. The surfactants examined in this study appear to 
reduce the transport of four compounds through the membrane. Overall, there was an inverse 
relationship between surfactant present and the amount of compound permeated. It was also 
observable that the effect of surfactant on compound permeation was different for different 
surfactant types, and also for different compounds. This variance was thought to result from 
a variation in the interaction of the charged and neutral compound species with the surfactant 
head group, and/or the surface and core of the surfactant micelle. Comparing all four 
surfactants, CTAB appeared to facilitate the lowest flux of compound through silicone 
membrane.          
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Chapter 5: Prediction of the mechanism of the effect of surfactant 
on compound permeation through silicone membrane.  
 
This chapter aims to predict the mechanism behind the effect of surfactant on drug 
permeation through silicone membrane. Analytical techniques such as differential scanning 
calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy and scanning electron 
microscopy (SEM) were used to investigate the physicochemical properties of the untreated 
and surfactant-treated membrane whereas nuclear magnetic resonance (NMR) spectroscopy 
was used to examine the behaviour of two surfactants in the solution with or without the 
membrane being present.    
 
5.1 Introduction 
 As mentioned in Chapter 4, a previous study in our laboratory investigated the effects 
of two surfactants, namely, sodium dodecyl sulphate (SDS) and Brij 35, on the permeation 
of two paraben derivatives through PDMS membrane (Waters et al.  2013). The study found 
that the presence of SDS significantly reduced the permeation of the parabens, whereas the 
presence of Brij 35 had no substantial effect on their permeation. The authors postulated that 
SDS molecules were impregnated within the membrane creating a charged barrier, thus 
repelling the paraben molecules attempting to permeate, although the exact mechanism was 
yet to be confirmed using further analytical techniques.  
Surfactants are known to self-assemble into micelles upon reaching the critical 
micelle concentration (CMC) with a mixture of monomers and pre-micelles at concentrations 
lower than this value. A study by Khossravi proposed that surfactant reduced drug permeation 
by entrapping drug molecules within its micelles (Khossravi 1997), which may be analogous 
to that observed here, yet the mechanism was not confirmed by further investigation. In this 
study, a number of analytical techniques, namely, differential scanning calorimetry (DSC), 
scanning electron microscopy (SEM), Fourier transform infrared (FTIR) and nuclear 
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magnetic resonance (NMR) spectroscopies were used to investigate the interactions between 
PDMS membrane and different surfactants to enhance our understanding of how some 
surfactants alter drug permeation through the membrane, yet some do not.     
 
5.2 Results and discussion 
5.2.1 Differential scanning calorimetry (DSC) 
 Differential scanning calorimetry (DSC) was employed to investigate whether the 
surfactant-treatment of PDMS membrane induced any structural change of the membrane. 
The surfactants were selected to encompass all four types – SDS (anionic), Brij 35 and Tween 
80 (non-ionic), CTAB (cationic), and CHAPS (zwitterionic). Fig. 5.1 shows the DSC 
thermograms of PDMS membranes, either untreated or pre-treated in the surfactant solutions.       
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1: DSC thermograms of PDMS membrane – untreated or pre-treated   
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The onset, and crystalline melting point temperatures for the samples are given in 
Table 5.1. For the untreated membrane the crystalline melting point was at -39.94 °C, which 
is consistent with the literature value of -40.00 °C (Dias et al.  2007). The DSC curves for 
the pre-treated samples were compared with that of the untreated membrane to observe any 
characteristic change that might result from the treatment with the surfactant solutions. 
Table 5.1: Values of onset and crystalline melting temperatures for PDMS membranes either 
untreated or pre-treated in different solutions 
Treatment type Onset temperature (°C) Crystalline melting point (°C) 
Untreated membrane  – 41.83 °C  – 39.94 °C 
No surfactant – 42.68 °C – 40.20 °C 
SDS 20 mM – 42.79 °C – 40.20 °C 
CTAB 20 mM – 42.50 °C – 40.19 °C 
Brij 35 20 mM – 42.62 °C – 40.05 °C 
CHAPS 20 mM – 42.75 °C – 40.22 °C 
Tween 80 20 mM – 42.49 °C – 40.05 °C 
 
 From Fig. 5.1 and Table 5.1 it is clear that none of the surfactants appeared to produce 
a significant shift in the crystalline melting point of the membrane, and the DSC thermograms 
for all of the treated samples are very similar to that for the untreated sample. Moreover, there 
was no additional peak formed in any of the DSC curves for the treated membranes. These 
findings suggest that the surfactants under investigation do not interact with the PDMS 
structure. This is because any interaction with the membrane structure would result in a clear 
shift of the crystalline melting point of the membrane, as stated in a previous study, whereby, 
upon treatment with IPM (isopropyl myristate), PDMS showed a shift in its crystalline 
melting point to a lower temperature, whereas no shift was observed for the treatment with 
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propylene glycol and decanol (Dias et al.  2007). With regards to the permeation effect of the 
surfactants discussed in Chapter 4, the DSC data indicates that the surfactants do not reduce 
the permeation of the compounds across PDMS membrane by interacting with or altering the 
bulk structure of the membrane.       
 
5.2.2 FTIR (Fourier transformed infrared) spectroscopy 
 Previously, DSC results suggested that the surfactants did not alter the 
physicochemical properties of PDMS membrane. To further confirm the DSC findings, FTIR 
spectroscopy was utilised to investigate any possible structural change in PDMS membrane 
owing to its treatment in the surfactant solutions. This technique is frequently used to 
characterise chemical structure or to identify any structural change (Chen et al. 2009). Fig. 
5.2 shows the FTIR spectra of the untreated and pre-treated samples, with the latter being 
soaked overnight in the surfactant solutions.     
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Fig. 5.2: FTIR spectra of PDMS samples – untreated, and pre-treated  
 
 It is apparent from Fig. 5.2 that all of the spectra are very similar, with the intensities 
of the peaks also being identical. It is also to be noted that no appreciable water content was 
found by FTIR spectroscopy. Moreover, no further peak was formed except the peaks for the 
untreated PDMS membrane, and no band from the surfactants was observed.  These findings 
can further be confirmed by looking at the values of the major peaks of the FTIR spectra for 
all samples (Table 5.2). The peak values for the untreated sample were used as reference to 
evaluate other spectra. For the untreated PDMS, the characteristic peak at 2962.0 cm-1 was 
assigned to the asymmetric and symmetric stretching vibrations of C-H bonds of the methyl 
group (Juárez-moreno et al.  2015). The peaks at 1258.1 cm-1 and 784.2 cm-1 are associated 
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with Si-(CH3)2 (Zhang et al.  2011), whereas the peak at 1006.3 cm
-1 is attributed to the 
stretching vibration of Si-O bond of the backbone of PDMS structure (Paschoal et al.  2011). 
When comparing the absorption bands for all spectra, it is obvious from Table 5.2 that there 
is no significant variation in their values.       
Table 5.2: The major peak values of the typical FTIR spectra of PDMS membranes – 
untreated or pre-treated in surfactant solutions 
Treatment type 
Values of absorption bands (cm-1) for different bonds present in 
PDMS structure 
C-H Si-(CH3)2 Si-O Si-C 
Untreated 
membrane 
2962.0 1258.1 1006.3 784.2 
No surfactant 2961.8 1258.1 1006.2 785.9 
20 mM SDS 2961.7 1258.1 1006.7 783.7 
20 mM CTAB 2962.0 1258.1 1007.8 783.4 
20 mM Brij 35 2961.7 1258.1 1008.2 783.1 
20 mM CHAPS 2961.9 1258.1 1007.7 784.0 
20 mM Tween 80 2961.8 1258.1 1006.5 783.5 
  
 Using FTIR spectroscopy it is possible to identify any change in a chemical structure 
by looking at the intensity of absorbance signal or the formation of a new peak. For example, 
the intensity of an absorbance signal may become weak because of a cross-linking 
modification (Han et al.  2011), or new peaks can be formed as a consequence of the change 
in PDMS structure by a chemical, for example, tetraethylorthosilicate (Chen et al.  2009).  
None of the above-mentioned phenomena was observed in this study. Therefore, it can be 
said that the structure of PDMS membrane remains intact in the presence of the surfactants. 
Again, in relation to the surfactant effect on compound permeation discussed in Chapter 4, 
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the FTIR results conform to the DSC findings whereby the mechanisms for reducing 
compound permeation were not associated with the structural modification of PDMS 
membrane.    
 
5.2.3 Scanning electron microscopy (SEM) 
The surfaces of the untreated, and pre-treated PDMS membranes were examined by 
scanning electron microscopy. Fig. 5.3 shows the microscopic images for different 
membrane samples.  All of the images illustrate a certain degree of asymmetry and patterned 
surface associated with these membranes. It is known that polymeric membranes such as 
PDMS, often have patterned surfaces that are advantageous to compound permeation, and 
any change in the pattern can alter permeability across the membrane (Redondo et al.  2001). 
To investigate whether the presence of surfactant induces any change in the patterned PDMS 
surface, the morphology of the pre-treated membranes was compared with that of the 
untreated sample. It is apparent from Fig. 5.3 that the surfactant-treatment does not alter the 
morphology of PDMS membrane, with all of the images showing a significant similarity. 
Therefore, with regards to the permeation effect of the surfactant (discussed in Chapter 4), 
SEM data suggests that the mechanism behind the barrier effect is not associated with the 
morphological changes of PDMS membrane.       
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Fig. 5.3: SEM micrographs of the untreated, and pre-treated PDMS surfaces 
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5.2.4 Nuclear magnetic resonance (NMR) spectroscopy 
  Previously, the morphology and chemical structure of PDMS membrane were 
analysed both in the presence and absence of surfactants to predict the mechanism behind 
their effect on compound permeation across the membrane, and based on DSC, FTIR and 
SEM, it was found that the mechanism is not associated with the morphology or structure of 
the membrane. In this section, the behaviour of surfactant in aqueous solution was examined 
using 1H NMR spectroscopy. Primarily, two surfactants were selected – SDS and Brij 35. 
These surfactants were reported in a previous permeation study (Waters et al.  2013) whereby 
SDS was found to reduce compound permeation across PDMS membrane with Brij 35 
showing no appreciable effect. However, in this study, both of the surfactants appeared to 
reduce the permeation of compounds across the membrane. To investigate the anomaly with 
regards to Brij 35, and also to predict the mechanism of the surfactant effect on compound 
permeation, NMR studies of the surfactants were conducted. 
 In the first set of experiments, the chemical shifts for H1 and H5 for SDS were 
measured at five different concentrations both in the presence and absence of PDMS 
membrane. The results are shown in Table 5.3. The proton numbering of the chemical 
structure of SDS is shown in Fig. 5.4. 
  
Fig. 5.4: Chemical formula of SDS with proton numbering (Cui et al.  2008) 
 
 
 
 
 
 
 
 
 
 
    CH3 (CH2)8CH2CH2CH2SO4
− −Na+ 
       H1        H2        H3     H4    H5 
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Table 5.3: Chemical shifts (ppm) for H1 and H5 protons of SDS in the presence and absence 
of PDMS membrane 
 Chemical Shift (ppm) H1 Chemical Shift (ppm) H5 
4 mM SDS 0.7447 3.9151 
4 mM SDS + membrane 0.7429 3.9143  
6 mM SDS 0.7448 3.9152 
6 mM SDS + membrane 0.7451 3.9152 
8 mM SDS 0.7466 3.9134 
8 mM SDS + membrane 0.7462 3.9137 
10 mM SDS 0.7545 3.9083 
10 mM SDS + membrane 0.7582 3.9129 
20 mM SDS 0.7576 3.8955 
20 mM SDS + membrane 0.7554 3.9089 
 
 The aim of the chemical shift measurements was to find out if there were any 
significant changes in the chemical shifts of SDS before and after the immersion of PDMS 
membrane in the SDS solutions. Any changes in the chemical shifts would indicate a change 
in SDS concentration, based on a study by Cui et al. (Cui et al. 2008). The study found that 
a decrease in SDS concentration resulted in a decrease in the chemical shift for H1 proton 
accompanied by an increase in that for H5 proton, and vice versa. The study also mentioned 
that the chemical shifts move to the high-frequency side as the concentration increased, and 
when the surfactant concentration reached its CMC, the chemical shift changed significantly 
with the increase in concentration, which implied micelle formation. In this study, it was 
hypothesised that the immersion of PDMS membrane would change the chemical shifts of 
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SDS. To comprehend this phenomenon, the experimental procedure can be considered. The 
sample solution was kept in a small volumetric flask with or without the pieces of PDMS 
membrane placed at the bottom of the flask. The samples for NMR were taken from the upper 
regions of the solutions i.e. considerably far from the membrane. It was assumed that a 
number of SDS molecules would be adsorbed on the membrane surface (PDMS membrane 
is hydrophobic in nature, and hence the hydrophobic tail of the surfactant can be impregnated 
into the membrane surface), subsequently decreasing the number of the molecules in the rest 
of the solution i.e. a decrease in SDS concentration. In such a scenario, a decrease in SDS 
concentration would happen in the upper part of the solution, which is not adjacent to the 
membrane. Therefore, it was expected that there would be significant changes in the chemical 
shifts of SDS upon immersing PDMS membrane in the solution which would in turn indicate 
a decrease in SDS concentration. However, it is apparent from Table 5.3 that the variations 
in chemical shifts that occurred upon the addition of PDMS membrane for all concentrations 
studied are not significant. For all cases, the changes in the chemical shifts are in the third or 
fourth decimal places. Overall, it can be said that the NMR data does not show any 
meaningful change when comparing the SDS solutions with those which have had PDMS 
membrane immersed in them. It might also be that the NMR method used in this study is not 
sensitive enough to detect small changes in SDS concentration upon the immersion of PDMS 
membrane.   
 In the second set of experiments, the behaviour of Brij 35 was examined at two 
different concentrations both in the presence and absence of PDMS membrane. The chemical 
shifts for H2 and H7 protons of Brij 35 were measured and are presented in Table 5.4. The 
formula of the surfactant with proton numbering is shown in Fig. 5.5.    
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Fig. 5.5: Chemical formula of Brij 35 with proton numbering (Hongchang et al.  2002) 
 
Table 5.4: Chemical shifts (ppm) for H7 and H2 protons of Brij 35 in the presence and 
absence of PDMS membrane 
 Chemical Shift (ppm) H7 Chemical Shift (ppm) H2 
1 mM Brij 35 0.7701 3.5267 
1 mM Brij 35 + membrane 0.7708 3.5269 
10 mM Brij 35 0.7798 3.5456 
10 mM Brij 35 +membrane 0.7803 3.5461 
 
 It can be seen in Table 5.4 that for both samples in the presence of the membrane, 
there was no significant change in the chemical shifts of Brij 35, a scenario similar to SDS.  
Therefore, it can be said that the concentration of Brij 35 remained unchanged in the presence 
of the membrane, and there could be a tendency for Brij 35 molecules to stay in the solution 
rather than being adsorbed into the membrane surface. These findings can help explain the 
phenomenon observed in a previous study that compound permeation across silicone 
membrane is ‘blocked’ by the adsorption of SDS on the membrane surface resulting in a 
reduction in permeation, yet Brij 35 does not exhibit the same effect (Waters et al. 2013). 
However, in this study (Chapter 4) Brij 35 was found to reduce compound transport through 
silicone membrane. One explanation of this anomaly could be that in a micellar solution of 
Brij 35, the compounds that are considered in this study – benzocaine, benzotriazole, 
ibuprofen and lidocaine – interact with and become entrapped within the hydrophobic core 
of the micelles, thus reducing their permeability through the membrane whereas the 
compounds considered in the previous study, namely methylparaben and ethylparaben, do 
CH3 (CH2)9 CH2 CH2OCH2CH2O(CH2CH2O)21CH2CH2OH 
H7      H6     H5   H4    H1             H2              H3 
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not show such interaction thus not having any effect on their permeation. However, a 
calorimetric study of Brij 35 and the compounds would be useful to confirm the above-
mentioned phenomena and hence remains the focus of a current study. 
 In the case of SDS, though the NMR data did not show any meaningful changes when 
comparing the SDS solutions with or without PDMS membranes, however, based on the 
DSC, FTIR and SEM data, and the findings by Waters et al. (Waters et al. 2013), two 
mechanisms can be suggested for the permeation effect of this surfactant. Firstly, the 
surfactant molecules are adsorbed on the membrane surface with their charged head group 
exposed to the donor solution of the diffusion cell thus preventing the permeation of the 
neutral drug molecules by repelling them away from the membrane. Secondly, the surfactant 
micelles can bind with, or entrap the drug molecules in their hydrophobic core (Tehrani-
Bagha & Holmberg 2013) and thus stop them passing through the membrane. The 
aforementioned mechanisms are illustrated in Figs. 5.6 and 5.7. These mechanisms can also 
be related to the permeation effect of other surfactants that were discussed in Chapter 4, 
namely, CTAB, CHAPS and Tween 80.   
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Fig. 5.6: Drug permeation across silicone membrane in the absence of the surfactant in the 
donor solution 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.7: Drug permeation across silicone membrane in the presence of the surfactant in the 
donor solution 
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5.3 Conclusion 
DSC, SEM, FTIR and NMR spectroscopy were used to predict the mechanism behind 
the effect of the selected surfactants on drug permeation across silicone membrane. The DSC, 
FTIR and SEM studies of the untreated and surfactant-treated membrane indicate that the 
surfactants do not reduce the drug transport across the membrane by altering either the 
chemical structure or the surface morphology of silicone membrane. NMR studies of two 
surfactants, namely, SDS and Brij 35, did not show significant differences when comparing 
the surfactant solutions with or without PDMS membrane. However, from DSC, SEM, FTIR 
and permeation data it can be suggested that the drug molecules are entrapped within the 
surfactant micelle and/or repelled, or blocked by the surfactant-impregnated membrane 
surface, with both of the cases resulting in a reduced permeation of drugs across the 
membrane. However, additional studies such as calorimetric investigation of drug-surfactant 
interaction would be helpful to further characterise the system under investigation.    
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Chapter 6: Plasma surface modification of polydimethylsiloxane 
membrane and its effect on the permeation of pharmaceutical 
compounds 
 
Previous chapters investigated the effects of several factors, namely the ionisation of 
compounds, the presence of surfactants in the donor solution, on the compound permeation 
through polydimethylsiloxane (PDMS) membrane. This chapter highlights the modification 
of PDMS membrane using plasma treatment, and its implication in the permeation study of 
five model compounds. Moreover, the stability of the treatment will be examined through 
aging studies of the modified membranes.      
 
6.1 Introduction 
 Polydimethylsiloxane (PDMS) is a commonly used attractive polymer based on many 
advantages it possesses such as high optical transparency, biocompatibility, thermal stability, 
low toxicity (Bacharouche et al.  2013) and gas permeability (Markov et al.  2014). The wide-
ranging use of PDMS includes environmental control (Turner & Cheng 1998), air separation 
(Kujawska & Kujawski 2015; Li et al.  2013), liquid mixture separation (Dong et al.  2014), 
microfluidics (Fan et al.  2015), wound dressings and medical applications (Agarwal et al.  
2012; Juárez-moreno et al.  2015), and biochemical sensing (Gu et al.  2013). In spite of 
many advantages, PDMS membrane often needs modification of its surface to enhance its 
suitability, particularly in the area of microfluidics. This is because of the easy and strong 
interaction of biological samples with the PDMS surface which is inherently hydrophobic. 
There are numerous applications of modified PDMS surface including cell culture, DNA 
hybridisation (Hsu & Chang 2015), biomolecule separation and immunoassay (Ko et al.  
2008).   
 A number of techniques have been employed to modify the surface of PDMS 
including physical or chemical treatments, or a combination of both. In particular, plasma 
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treatment has widely been used, in recent years, for modification of the PDMS surface (Bodas 
et al.  2008). Plasma treatment is capable of altering the surface polarity and wettability of 
most polymers (Kull et al.  2005). It is generally accepted that during plasma treatment the 
methyl groups (–CH3) of PDMS surface are removed and replaced with hydroxyl groups (–
OH) (S. Bhattacharya, A. Datta, J. M. Berg 2005) resulting in an oxidised membrane surface. 
This creates a hydrophilic PDMS surface which can be observed through a significant 
reduction in the water contact angle (WCA) (Deshpande et al.  2012). As a consequence of 
this modification, the properties of the membrane transforms, for example, it has been 
reported that freshly treated (oxidised) PDMS showed a substantially smaller gas diffusion 
coefficient relative to untreated membrane (Markov et al.  2014). In some studies plasma 
treatment process is the first stage in a series of procedures to change the surface i.e. to create 
various complex products that again, possess different properties to the original PDMS or 
evade some disadvantages. For instance, following plasma treatment compounds can be 
incorporated onto the treated surface to minimise nonspecific protein adsorption thus 
expanding the use of PDMS-based microfluidic chips to carry out complex biological 
investigation (Yu et al.  2015). 
 One issue with plasma treatment is that the hydrophilicity of the treated surface may 
disappear during aging, and the surface can recover its hydrophobicity over time.  One study 
investigated the hydrophobic recovery of plasma-treated PDMS surface stored either in air 
or under water (Markov et al.  2014). It was found that in the presence of air the treated 
surface recovered hydrophobicity after 3 days. Interestingly, storage under water delayed 
recovery for ~ 3 weeks. Moreover, the study compared two types of PDMS membrane – 
standard and highly cross-linked. It was observed that, in the presence of air, it took only 3 
days for the standard membrane to recover whereas for the highly cross-linked membrane 
the surface was not restored even after a 3-week aging period. In another study, 
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polyethersulfone (PES) membrane, which is also hydrophobic in nature, was modified to 
have a hydrophilic surface using plasma treatment (Kull et al.  2005). Interestingly, their 
modified membrane did not show any hydrophobic recovery even 12 months after treatment 
i.e. the hydrophilicity of the membrane was stable for 12 months. It is important to mention 
that hydrophobic recovery needs to be eliminated or reduced to prolong the shelf life of 
modified membrane for practical applications.  
 One important area of topical and transdermal research is the use of PDMS membrane 
to predict the permeation of pharmaceutical compounds across skin. Consequently, PDMS 
has been suggested, in recent years, as a reliable, economic and ethical alternative for 
measuring compound permeation together with a variety of other techniques (Waters 2015). 
Although, PDMS has been utilised in a significant number of drug diffusion studies, no 
known study has previously focused on the implication of plasma-treated PDMS in drug 
diffusion experiments. In the current study, the surface of PDMS membrane was modified 
using plasma treatment. The treated membranes were characterised by a number of surface 
analytical techniques such as contact angle measurement, SEM (scanning electron 
microscopy), and EDX (energy dispersive X-ray) analysis. Moreover, we reported the first 
study aimed at understanding the impact of plasma surface modification on permeation of a 
set of model compounds with the intention of creating a more hydrophilic, and thus 
potentially more suitable, in vitro skin mimic. The hydrophilic stability of the treated 
membrane was examined using in vitro drug diffusion studies and EDX analysis.       
       
6.2 Results and discussion 
6.2.1 Surface modification of PDMS membrane 
 PDMS is known to have a hydrophobic surface which can be modified with the 
application of plasma surface treatment. In this study, the surface of PDMS membrane was 
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exposed to air plasma to make it more hydrophilic. Water contact angle (WCA) was used to 
assess the change in membrane hydrophilicity induced by plasma treatment. WCAs were 
measured for both treated and untreated PDMS membrane. The WCAs were plotted as a 
function of the age of the water drop (Fig. 6.1). Figure 6.1 shows that the contact angle was 
significantly reduced after plasma treatment of the membrane surface. Therefore, it can be 
inferred that the hydrophobicity of PDMS surface was reduced by the plasma treatment, as 
expected based on previous literature (Bodas et al.  2008).    
  
Fig. 6.1: Static contact angles for water on a PDMS membrane untreated or plasma-treated   
  
In addition to the contact angle measurement, the reduction in the hydrophobicity of 
the PDMS surface was further evidenced by SEM-EDX analysis. The elemental composition 
(C, O & Si) of PDMS surface untreated, and plasma-treated, was measured using SEM-EDX, 
and the results are presented in Table 6.1. 
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Table 6.1: Percentage of weight of chemical elements at the surface of PDMS membrane 
before and after the plasma treatment. [The data are presented as mean ± SD, (n = 3)] 
 
The results in Table 6.1 clearly demonstrate that following the plasma treatment of PDMS 
surface there was an increase in oxygen content with a subsequent decrease in carbon content. 
More specifically, the oxygen content of the membrane surface increased by ~ 17 % with a 
concomitant decrease in carbon content (by ~ 16 %). It is evident from literature that during 
plasma treatment the methyl groups (–CH3) of PDMS membrane surface are removed and 
replaced with hydroxyl groups (–OH) (Markov et al.  2014). The same process could be 
observed here i.e. the plasma treatment resulted in an increase in the hydroxyl (–OH) groups 
with a concomitant decrease in methyl (–CH3) groups at the membrane surface. In other 
words, the treatment incorporates a significant concentration of oxygen containing functional 
groups at the membrane surface. These functional groups are covalently bonded to the 
polymeric backbone with the formation of silanol groups (Si–OH). Thus, following plasma 
treatment, the surface of PDMS membrane became more hydrophilic.  
 
6.2.2 Membrane integrity 
 Fig. 6.2 shows SEM images of PDMS membrane surfaces. Images for both treated 
and untreated membranes illustrate a certain degree of asymmetry associated with these 
membranes. It can also be seen that the plasma treatments did not cause any obvious damage 
Element 
% of weight of elements at PDMS membrane surface 
Untreated Membrane Plasma Treated Membrane 
Carbon (C) 46.33 ± 2.69 30.68 ± 2.26 
Oxygen (O) 29.86 ± 2.21 46.49 ± 2.44 
Silicone (Si) 23.82 ± 2.09 22.84 ± 2.20  
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to the membrane surfaces. Therefore, the membrane integrity was not compromised by these 
treatments.   
 
 
 
 
 
 
 
Fig. 6.2: SEM micrographs of the surface of untreated and plasma-treated PDMS membrane 
 
6.2.3 Effect of surface modification of PDMS membrane on compound permeation 
The permeation of five model compounds was carried out through silicone (PDMS) 
membrane prior to plasma treatment, and immediately after the treatment. The model 
compounds were benzocaine, benzotriazole, caffeine, ibuprofen and lidocaine. These 
compounds have a diverse range of lipophilicities ranging from a log P of -0.07 for caffeine 
(Waters et al. 2013) to 3.6 for ibuprofen (Waters & Bhuiyan 2016) i.e. to encompass both 
hydrophilic and hydrophobic types. For all compounds, the pH of the donor and receptor 
solutions was 7.4. The percentages of compounds unionised were 0.000024 %, 86.32 %, 
0.00000013 %, 0.32 % and 24.02 % for benzocaine, benzotriazole, caffeine, ibuprofen and 
lidocaine, respectively.   
The effects of PDMS surface modification on the permeation of the model 
compounds are graphically presented in Figs. 6.3 – 6.7. In addition to the graphical 
presentations, two permeation parameters i.e. 𝐽 (steady-state flux) and Q6 (cumulative 
amount permeated after 6 hours) were calculated, and the values are shown in Table 6.2 and 
6.4. The flux values were statistically analysed using One-way ANOVA, and the calculated 
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p-values for each compound are shown in Table 6.3. The p-values were employed to identify 
any significant difference in compound permeation owing to the modified membrane surface. 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3: Permeation profiles of benzocaine through PDMS membrane untreated or plasma-
treated 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4: Permeation profiles of benzotriazole across PDMS membrane untreated or plasma-
treated 
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Fig. 6.5: Permeation profiles of caffeine across PDMS membrane untreated or plasma-treated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.6: Permeation profiles of ibuprofen across PDMS membrane untreated or plasma-
treated 
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Fig. 6.7: Permeation profiles of lidocaine across PDMS membrane untreated or plasma-
treated. 
  
It can be seen in Figs. 6.3 – 6.7 that the permeation profiles of all compounds, except 
for caffeine, were significantly affected by the plasma-modified PDMS surface. A more 
specific and quantitative view of this phenomenon can be obtained from the data presented 
in Table 6.2, 6.3 and 6.4. The data in these tables indicate that the plasma modification of 
PDMS resulted in a significant change (p < 0.05) in the flux of all compounds across the 
membrane, with caffeine being the exception (p > 0.05). The lower flux values of benzocaine, 
benzotriazole, ibuprofen and lidocaine obtained with the plasma-modified PDMS surface 
show a clear interaction between these compounds and the modified membrane. However, 
caffeine was found not to have an observable interaction with the modified PDMS surface. 
It is obvious from the above-mentioned facts that the modification of membrane surface does 
play an important role in compound permeation.          
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Table 6.2: Steady-state flux values of five model compounds across untreated or plasma-
treated silicone membrane 
 
 
Table 6.3: p-values calculated using ANOVA test for each drug 
Drug p-values 
Benzocaine 0.004 
Benzotriazole 0.001 
Caffeine 0.308 
Ibuprofen 0.000 
Lidocaine 0.000 
 
 
 In addition to the flux values, this study also calculated the cumulative amount of 
compound permeated after 6 h and the results are presented in Table 6.4. The purpose of such 
calculation was to understand the extent of reduction in permeation owing to the plasma 
treatment of PDMS membrane. Using the data in Table 6.4, the percentage of compound 
permeated after 6 h was calculated and shown in Table 6.5 and Fig. 6.8. In Table 6.5 the 
amount of compound permeated after 6 h across untreated membrane was considered 100 %, 
and then the calculation for plasma-treated membrane was performed accordingly. Such 
Compound 
Steady-state flux (µg/cm2/h) of compounds across PDMS membrane 
Untreated Membrane Plasma Treated Membrane 
Benzocaine 97.03 ± 2.52 62.89 ± 9.80 
Benzotriazole 11.05 ± 0.71 6.57 ± 0.62 
Caffeine 4.57 ± 0.32  4.14 ± 0.56 
Ibuprofen 35.26 ± 1.30 10.03 ± 0.81 
Lidocaine 76.97 ± 2.47 43.07 ± 2.50 
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presentation provides a convenient way of comparing different model compounds with 
regards to the effect of a modified membrane on their permeation.   
 
Table 6.4: The values of cumulative amount permeated after 6 hours (Q6) of five model 
compounds across untreated or plasma-treated silicone membrane 
 
 
Table 6.5: The values of percentage (%) permeated after 6 hours of five model compounds 
across untreated or plasma-treated silicone membrane 
 
Compound 
Q6 values (µg/cm
2) of compounds across PDMS membrane 
Untreated Membrane Plasma-treated Membrane 
Benzocaine 566.59 ± 13.67 363.41 ± 55.81 
Benzotriazole 65.65 ± 3.84 39.48 ± 3.63 
Caffeine 28.22 ± 1.86 24.85 ± 3.54 
Ibuprofen 214.48 ± 7.80 63.54 ± 4.90 
Lidocaine 453.72 ± 15.41 252.16 ± 15.59 
Compound 
% permeated of compounds after 6 hours across PDMS membrane 
Fresh Membrane Plasma-treated Membrane 
Benzocaine 100 ± 2.41 64.14 ± 9.85 
Benzotriazole 100 ± 5.85 60.14 ± 5.53 
Caffeine 100 ± 6.59 88.06 ± 12.54 
Ibuprofen 100 ± 3.64 29.63 ± 2.28 
Lidocaine 100 ± 3.40 55.58 ± 3.44 
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 It can be seen in Table 6.5 and Fig. 6.7 that the presence of the plasma-modified 
PDMS surface created a significant reduction in the permeation of benzocaine, benzotriazole, 
ibuprofen and lidocaine. This scenario, therefore, indicates that the modified membrane 
surface prevents these compounds passing across the membrane and passing into the receptor 
chamber of the flow-through diffusion cell. In contrast to this, the permeation of caffeine was 
not significantly affected by the modified membrane surface and hence no appreciable 
reduction in its permeation was observed. These findings portray that the plasma-treated 
PDMS surface is generating a barrier effect for the former four compounds, preventing their 
movement through the membrane – a situation not apparent with caffeine.   
 
 
 
 
 
 
Fig. 6.8: The values of percentage of compound permeated after 6 h through plasma-treated 
PDMS membrane. The % permeated was defined with respect to the corresponding value for 
the untreated membrane. 
 
As previously stated, plasma treatment replaces the methyl groups (–CH3) on the 
PDMS surface with hydroxyl groups (–OH), resulting in a predominant presence of oxygen 
containing functional groups on the membrane surface. Therefore, it can be postulated that 
the treatment of the membrane surface results in a significant number of the hydroxyl groups 
(–OH) being present at the membrane surface exposed to the donor solution of the flow-
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through diffusion cell, thus rendering the membrane surface hydrophilic. As benzocaine (log 
P of 1.9), benzotriazole (log P of 1.2), lidocaine (log P of 2.4) and ibuprofen (log P of 3.6) 
are lipophilic in nature, they could be reluctant to approach the plasma-treated membrane 
surface as it presents a hydrophilic environment thus repelling the compounds away from the 
membrane resulting in a reduced permeation through to the receptor chamber. However, 
although all four compounds experienced a reduction in permeation owing to the plasma 
treatment, the trend they follow is not the same. From Table 6.5, if the extent of overall 
reduction for these four compounds is positioned in an order, then it appears as ibuprofen > 
lidocaine > benzocaine > benzotriazole. Considering the log P values of these compound the 
order suggests that the higher the log P the greater the reduction in compound permeation. In 
other words, the compound with a higher lipophilicity faces a greater barrier effect from the 
plasma-modified hydrophilic PDMS surface, as hypothesised. Ibuprofen, with a log P value 
of 3.6, experienced a reduction of ~ 70 %, being the highest when compared with the other 
compounds, and benzocaine, with a log P value of 1.9, had a reduction of ~ 36 %, being the 
lowest. As caffeine is hydrophilic in nature, the same phenomenon i.e. the barrier effect from 
the plasma-treated hydrophilic surface would not occur to repel caffeine away from PDMS 
membrane, and hence no reduction in permeation would result. Thus, the permeation profile 
of caffeine through the untreated and treated silicone membrane would be similar. However, 
one might expect that, as the treated surface becomes hydrophilic, it should enhance caffeine 
permeation which was not observed in this study. This is because though the surface becomes 
hydrophilic after the plasma treatment, the core of the membrane remains hydrophobic in 
nature. In other words, the core remains unchanged for both the treated and untreated 
membranes as plasma treatment only works at surface level. As prior to transport into a 
receiver compartment of diffusion cell, caffeine molecules permeate through the hydrophobic 
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core, their permeation rate would be similar for both treated and untreated silicone 
membrane.  
In addition to log P values, two other physicochemical properties, namely the number 
of hydrogen bond donors, and hydrogen bond acceptors, of the model compounds were also 
considered to investigate if there is an effect of these properties on compound permeation 
through plasma treated membrane. The properties are tabulated below (Table 6.6). 
Table 6.6: The physicochemical properties1 of the model compounds  
 Benzocaine Benzotriazole Caffeine Ibuprofen Lidocaine 
H bond 
acceptors 
2 1 6 1 1 
H bond 
donors 
3 3 0 2 3 
1The physicochemical properties were generated from ACD/Labs, RSC, UK 
Comparing the data in Table 6.5 and 6.6, it is apparent that there is no observable 
relationship between the percentages permeated of the compounds through the plasma-
treated membranes and the number of hydrogen bond donors/acceptors of the compounds. 
Therefore, it can be inferred that, even though the hydrogen bond donors/acceptors of the 
compounds may interact with the hydroxyl groups on the surface of the plasma-treated 
membrane, such interactions would not significantly affect compound permeability through 
the plasma-treated membrane.          
6.2.4 Stability studies of plasma treated PDMS membrane 
  It is clear from the above-mentioned discussion that plasma treatment does create a 
permeability barrier for compounds by creating a hydrophilic membrane surface. However, 
as mentioned earlier, the hydrophilic stability of the treated surface can be time-dependent 
(Kull et al.  2005). Studies suggest that the hydrophilic stability of plasma treated membrane 
varies depending on the type and composition of the membrane, and also the sample storage 
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condition (Markov et al.  2014). However, none of the above-mentioned studies considered 
the storage of membrane samples under airtight conditions. Moreover, the effect of aging of 
the plasma-treated silicone membrane on compound permeation is yet to be known. In this 
study, the plasma-treated PDMS membrane was aged for 1, 2, 4 and 8 weeks under airtight 
conditions at room temperature. The aged samples were then used in the permeation study of 
a model compound, namely lidocaine. The pH of the donor and receptor solutions used in the 
permeation study was 7.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.9: Permeation profiles of lidocaine through PDMS membrane before and after the 
plasma-treatment. Note: the plasma-treated samples were used either immediately after the 
treatment or aged over a period of 1, 2, 4 and 8 weeks prior to the permeation experiments 
  
The permeation of lidocaine through the aged samples was then compared with that 
through the untreated membrane to examine the hydrophilic stability of the treated membrane 
(Fig. 6.9). The data was also used to investigate the effect of aging of the treated membrane 
on lidocaine permeation.  It can be seen in Fig. 6.9 that the permeation profiles of lidocaine 
across the untreated and the aged treated membranes are clearly distinctive. For all of the 
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aged treated membranes, there was a significant reduction in lidocaine permeation when 
compared with the untreated samples. A quantitative view of this phenomenon can be 
obtained by looking at the data presented in Table 6.7 and 6.8. Table 6.7 shows the steady-
state flux values of lidocaine whereas Table 6.8 demonstrates the p-values calculated using 
ANOVA test.  
 
Table 6.7: Steady-state flux values of lidocaine across plasma-treated PDMS membrane with 
or without aging 
Length of aging Steady-state flux (µg/cm2/h) 
Untreated membrane 76.97 ± 2.47 
No aging (freshly treated) 43.07 ± 2.50 
1 week 26.99 ± 3.79 
2 weeks 30.26 ± 2.08 
4 weeks 32.4 ± 4.49 
8 weeks 25.42 ± 5.46 
 
 
Table 6.8: p-values calculated using ANOVA test 
 Untreated No aging  1 week 2 weeks 4 weeks 8 weeks 
Untreated  0.000 0.000 0.000 0.000 0.000 
No aging 0.000  0.004 0.002 0.023 0.007 
1 week 0.000 0.004  0.260 0.186 0.704 
2 weeks 0.000 0.002 0.260  0.496 0.225 
4 weeks 0.000 0.023 0.186 0.496  0.163 
8 weeks 0.000 0.007 0.704 0.225 0.163  
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It is obvious from Table 6.7 that the flux values obtained for the untreated and the 
aged treated membranes are different, and the p-values in Table 6.8 show that the difference 
in lidocaine fluxes is significant (p < 0.05) when comparing the flux values through the 
untreated membrane with that through any of the aged treated membranes. Moreover, all of 
the aged treated samples drastically reduced lidocaine permeation (Table 6.7), a phenomenon 
also observed for the freshly treated membrane (no aging). It was mentioned in the previous 
section that the permeation of the hydrophobic lidocaine was reduced because of the presence 
of a hydrophilic membrane surface resulting from the plasma treatment. Therefore, these 
findings imply that the plasma-treated membranes retain their hydrophilic surfaces even after 
8 weeks of storage under airtight condition, thus producing a permeability barrier for the 
hydrophobic lidocaine.  
 However, it is known from literature that the hydrophilic surface of plasma-treated 
PDMS membrane is thermodynamically unstable, and the treated membrane undergoes 
hydrophobic recovery with storage time (Bodas & Khan-malek 2007). Hydrophobic recovery 
is generally ascribed to the migration of unmodified low molecular weight chains from the 
bulk towards the surface and the diffusion of the oxidised species from the surface inside the 
bulk of PDMS polymer (Bacharouche et al.  2013). On the basis of these phenomena, one 
study mentioned that a polymeric membrane with a smaller amount of low molecular weight 
species would remain hydrophilic longer (Bodas et al.  2008). Another study, previously 
mentioned, found that the hydrophobic recovery could be delayed by using a highly cross-
linked PDMS membrane rather than a standard version (Markov et al.  2014). Thus, it can be 
postulated that the PDMS membranes, employed in this study, are highly cross-linked, and 
contain fewer low molecular weight species, thus showing a hydrophilic stability upon aging 
following the plasma treatment. Storage under airtight conditions can also contribute to the 
longer hydrophilic stability by preventing contamination of the treated surface from air 
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exposure. It is evident from literature that this decreases the hydrophilicity of the treated 
membrane surface (Bacharouche et al.  2013).   
 In addition to the permeation data, the hydrophilic stability of the plasma-treated 
membrane was also assessed by SEM-EDX analysis. For this purpose, the elemental 
composition (C, O and Si) of the treated surface, aged for 8 weeks, was determined using 
SEM-EDX and the data were then compared with the untreated surface (Table 6.9). 
Table 6.9: Percentage of weight of chemical elements at the surface of PDMS membrane, 
either untreated, or treated also with 8 weeks of aging  
 
It can be seen in Table 6.9 that for the plasma-treated surfaces, the oxygen and carbon 
content remain similar before and after the aging period. Therefore, it is obvious that aging 
under airtight conditions did not affect the hydrophilic stability of the treated surface. Overall, 
from the above-mentioned discussion it can be suggested that the hydrophilic stability of the 
plasma-treated PDMS surface can be maintained for a moderately long period (> 8 weeks) 
by storing the samples under airtight conditions.   
 The other interesting phenomenon is that the flux of lidocaine across any of the aged 
samples is significantly lower than that across the non-aged sample (Table 6.7), thus 
indicating that upon aging, even for only 1 week, the plasma-treated surface becomes more 
hindering to lidocaine permeation. Such an increase in hindrance might be because of the 
reorientation of the polar surface groups upon aging. However, the exact mechanism is yet 
Element % of weight of elements at PDMS membrane surface 
 
Untreated 
membrane 
Treated membrane 
with no aging 
Treated membrane with aging for 
8 weeks under airtight condition  
Carbon (C) 46.33 ± 2.69 30.68 ± 2.26 31.90 ± 2.37 
Oxygen (O) 29.86 ± 2.21 46.49 ± 2.44 43.01 ± 2.67 
Silicone (Si) 23.82 ± 2.09 22.84 ± 2.20  25.09 ± 2.46 
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to be known, and is the focus of a current study. It can also be seen in Table 6.8 that the fluxes 
of lidocaine through the treated samples, aged for 1, 2, 4, and 8 weeks, are not significantly 
different from each other (p > 0.05). Therefore, it can be postulated that the above-mentioned 
surface reorientation occurs within 1 week of aging, and the reoriented surface remains 
unchanged for any further period of aging i.e. 2, 4 and 8 weeks. Thus, all of the aged samples 
offer a similar flux of lidocaine.   
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6.3 Conclusion 
Hydrophilic PDMS membranes were created by air plasma treatment which resulted 
in the incorporation of oxygen containing polar functional groups at the membrane surface. 
The presence of these groups was confirmed by SEM-EDX analyses, which showed higher 
oxygen content in the treated membranes, compared with the untreated membrane. The 
hydrophilicity of the modified membrane was demonstrated by measuring water contact 
angle (WCA). The membrane integrity was examined using SEM images, which showed no 
physical damage of the treated membrane. The modified membranes appeared to reduce the 
permeation of the hydrophobic compounds, namely benzotriazole, benzocaine, ibuprofen and 
lidocaine, while not affecting the hydrophilic caffeine permeation. As the plasma treatment 
produced a hydrophilic surface, hydrophobic compounds would be reluctant to approach it. 
Moreover, it was found that the higher the log P of the compound, the greater the reduction 
in its permeation through the modified membrane.  
With respect to stability studies, the combined results of lidocaine permeation through 
aged samples and EDX analysis revealed that the modified membranes retained their 
hydrophilic stability even after aging for 8 weeks under airtight conditions. The reasons for 
the hydrophilic stability were assumed to be – 1) the highly cross-linked nature of the 
membrane and 2) the prevention of organic contamination of the modified membrane 
surfaces by storing them under air tight conditions.            
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Chapter 7: Conclusion and future work 
Chemical based skin mimics, for example, silicone membranes, are widely used to 
simulate the stratum corneum of skin in in vitro drug diffusion studies. In particular, 
polydimethylsiloxane (PDMS) membrane, simply known as silicone membrane, is frequently 
employed as an in vitro skin mimic, to aid the prediction of percutaneous absorption, and to 
perform the qualitative assessment of compounds. A number of attempts have been made to 
investigate factors affecting drug permeation across PDMS membrane, including those 
reported in this thesis. This study, also, found plasma surface treatment to be an economic, 
convenient and stable method of modifying silicone membrane to make it, potentially, a more 
suitable in vitro skin mimic.    
The objectives of this thesis, as mentioned in Chapter 1, were accomplished 
successfully, and are summarised below: 
1. To study the effect of ionisation on the permeation of drugs through silicone 
membrane.  
Chapter 3 investigated six model drugs, namely, 1-methyl-3-phenylpropylamine, 
benzoic acid, benzotriazole, ibuprofen, ketoprofen and lidocaine, to determine their 
permeation across PDMS membrane at three specific percentages of ionisation. Moreover, 
iGC SEA was employed to characterise the surface chemistry of the membrane. The data 
suggested that there was an overall linear relationship between the percentage unionised of 
the drugs and the amount permeated. In other words, permeation was preferable for the 
unionised forms for all drugs, though the membrane surface is basic in nature, as confirmed 
from the iGC SEA data, thus indicating that the overall hydrophobic nature of the membrane 
outweighs any possible surface effect. In summary, it can be said that formulation pH does 
play an important role in the permeation of drugs through silicone membrane.    
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2. To study the effect of surfactants on the permeation of drugs across silicone 
membrane. 
Chapter 4 examined the permeation of four model drugs, namely, benzocaine, 
benzotriazole, ibuprofen and lidocaine, through PDMS membrane in the presence of four 
types of surfactants – anionic (SDS), cationic (CTAB), non-ionic (Brij 35 and Tween 80) and 
zwitterionic (CHAPS). All of the surfactants were found to reduce the permeation of the 
drugs through the membrane, though the extent of the reduction varied for different 
surfactants. The variations in reduction effects were assumed to result from the variability of 
the interactions of drug species with the surfactant head groups and/or micelles. Overall, there 
was an inverse relationship between surfactant concentration and the amount of drug 
permeated over a period of 6 h. For benzocaine, benzotriazole and ibuprofen, the highest 
permeation-hindering effect came from CTAB, whereas for lidocaine, that was from SDS. 
CHAPS appeared not to have a significant effect on drug permeation, except for ibuprofen. 
   
3. To predict the mechanism of surfactant effect on drug permeation through silicone 
membrane. 
Chapter 5 aimed at predicting the mechanism of surfactant effects on drug permeation 
through PDMS membrane. DSC, FTIR spectroscopy and SEM were used to analyse the 
surfactant-treated PDMS membrane, whereas NMR was used to study the behaviour of two 
surfactants, namely, SDS and Brij 35, in solutions with or without PDMS membrane being 
present. The data from DSC, FTIR and SEM suggested that the surfactants do not alter either 
the physicochemical properties or chemical structure or morphology of the membrane, and 
therefore, the mechanisms for permeation-reduction effects by the surfactants were not 
associated with these. Although NMR data did not show any significant change, based on the 
data from DSC, SEM, FTIR and permeation studies, two mechanisms can be suggested – 1) 
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the binding or entrapment of the drug molecules within the surfactant micelles, and 2) the 
repulsion and/or obstruction of the drug molecules by the surfactant-impregnated membrane 
surface. Both of these mechanisms, alone or in combination, could result in a decrease in 
drug permeation across PDMS membrane. 
    
4. To investigate the effect of plasma surface modification of silicone membrane on 
the permeation of drugs. 
In Chapter 6, PDMS membrane surfaces were modified by air plasma treatment, and 
the permeation studies of five model drugs, namely, benzocaine, benzotriazole, caffeine, 
ibuprofen and lidocaine, were conducted using the modified membranes. The plasma-
induced hydrophilicities of the modified membranes were confirmed by the WCA 
measurements and SEM-EDX analysis. Moreover, SEM images of the modified membrane 
surfaces showed no apparent physical alteration following the plasma treatment. The 
permeation data revealed that plasma-induced hydrophilicity produced a significant 
reduction in the fluxes of the hydrophobic compounds (benzocaine, benzotriazole, ibuprofen 
and lidocaine), whereas the permeation of caffeine, which is hydrophilic, was unaffected. It 
was also observed that the higher the log P of the drug, the lower the flux through the plasma-
treated membrane.  
The stability of the plasma-modified PDMS membrane was analysed using SEM-
EDX and in vitro permeation studies. The modified membranes were aged for 1, 2, 4 and 8 
weeks under airtight conditions, and the permeation of lidocaine was performed using the 
aged membranes. The combined data from EDX analysis and permeation studies suggested 
that the hydrophilicities of the modified membranes lasted even after 8 weeks, which could 
be because of the highly cross-linked nature of PDMS membrane, and the absence of organic 
contamination of the membranes under airtight storage conditions.   
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Future work 
This work could be expanded through several avenues, including: 
a) Expansion of analytical techniques 
The magnitude of the reduction in drug permeation were dissimilar for different 
surfactants. To explain these phenomena, it would be useful to investigate the interactions 
between the drugs and the surfactants by isothermal calorimetry (ITC). Moreover, ITC could 
provide a detailed mechanistic picture of the surfactant effects. 
 The NMR studies were conducted only for SDS and Brij 35. Further NMR studies 
involving CTAB, CHAPS and Tween 80 would be helpful to enhance the understanding of 
the surfactant effects on drug permeation through PDMS membrane. 
 The elemental composition of the PDMS surface was analysed by SEM-EDX 
method. A better accuracy of such analysis could be obtained by X-ray photoelectron 
spectroscopy (XPS).    
b) Use of different plasma treatments and conditions 
This study used air plasma to modify the PDMS surface to have silanol (Si-OH) 
groups, thus rendering it hydrophilic. There is scope for using additional plasmas such as 
nitrogen-based plasmas (N2, NH3), which can incorporate amine functionalities on the PDMS 
surface, which can then be chemically reacted with suitable acyl chlorides to produce amide 
groups analogous to that present in the skin ceramides, thus broadening the possibility of 
using the membrane as a skin surrogate in in vitro drug diffusion studies. 
The plasma-treated membranes were stored under airtight conditions for the stability 
studies. Several other storage conditions, for example, under water, phosphate buffers and 
liquid nitrogen, could be explored to determine their effect on stability. There is also need to 
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investigate different treatment times and powers for the purpose of optimising experimental 
conditions.  
With regards to drug permeation through the modified membrane, more compounds 
and the calculation of more parameters, such as permeability coefficients (Kp), are needed to 
allow comparison of data with human or animal skin, or the in vivo situation. Such a 
comparison could be useful for the development of an effective in vitro skin mimic in the 
assessment of topical and transdermal products.  
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